

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Protocol for WeExPAnd: PrEP Demonstration Project among Women Vulnerable to HIV Infection in the US South

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-075250
Article Type:	Protocol
Date Submitted by the Author:	01-May-2023
Complete List of Authors:	<p>Psaros, Christina; Harvard Medical School Department of Psychiatry; Brigham and Women's Hospital Department of Emergency Medicine          Goodman, Georgia; Harvard Medical School Department of Psychiatry; Brigham and Women's Hospital Department of Emergency Medicine          McDonald, Victoria; The University of Alabama at Birmingham School of Nursing,          Ott, Corilyn; The University of Alabama at Birmingham Heersink School of Medicine; The University of Alabama at Birmingham School of Nursing          Blyler, Abigail; University of Pennsylvania School of Arts and Sciences          Rivas, Alexa; Harvard Medical School Department of Psychiatry          Shan, Liang; The University of Alabama at Birmingham School of Nursing          Campbell, Marquette; Whatley Health Services, Inc. - Maude L. Whatley Health Center          Underwood, Eric; Whatley Health Services, Inc. - Maude L. Whatley Health Center          Krakower, Douglas; The Fenway Institute at Fenway Health; Beth Israel Deaconess Medical Center          Elope, Latesha; The University of Alabama at Birmingham Heersink School of Medicine          Kudroff, Kachina; The University of Alabama at Birmingham Heersink School of Medicine          Sherr, Kenneth H.; University of Washington Department of Global Health          Kempf, Mirjam-Colette ; The University of Alabama at Birmingham Heersink School of Medicine; The University of Alabama at Birmingham School of Nursing</p>
Keywords:	HIV & AIDS < INFECTIOUS DISEASES, Feasibility Studies, Health Equity, Health Education, SEXUAL MEDICINE, Primary Prevention

SCHOLARONE™  
Manuscripts

1  
2  
3 **Protocol for WeExPAnd: PrEP Demonstration Project among Women Vulnerable to HIV**  
4  
5  
6 **Infection in the US South**

7  
8 Christina Psaros<sup>1,2</sup>, Georgia R. Goodman<sup>1,2,3</sup>, Victoria McDonald<sup>5</sup>, Corilyn Ott<sup>5,6</sup>, Abigail  
9  
10 Blyler<sup>4</sup>, Alexa Rivas<sup>1</sup>, Liang Shan<sup>6</sup>, Marquette Campbell<sup>10</sup>, Eric Underwood<sup>10</sup>, Douglas  
11  
12 Krakower<sup>3,8</sup>, Latesha Eloppe<sup>5</sup>, Kachina Kudroff<sup>5</sup>, Kenneth Sherr<sup>9</sup>, Mirjam-Colette Kempf<sup>5,6,7</sup>  
13

14  
15 1 Department of Psychiatry, Massachusetts General Hospital/Harvard Medical School,  
16 Boston, MA

17  
18  
19 2 Department of Emergency Medicine, Brigham and Women's Hospital, Boston, MA  
20

21  
22 3 The Fenway Institute, Fenway Health, Boston, MA  
23

24  
25 4 Positive Psychology Center, University of Pennsylvania, Philadelphia, PA

26  
27 5 School of Nursing, University of Alabama at Birmingham, Birmingham, AL

28  
29 6 School of Medicine, University of Alabama at Birmingham, Birmingham, AL

30  
31 7 School of Public Health, University of Alabama at Birmingham, Birmingham, AL  
32

33  
34 8 Beth Israel Deaconess Medical Center, Boston, MA

35  
36 9 Department of Global Health, University of Washington, Seattle, WA  
37

38  
39 10 Whatley Health Services, Inc. - Maude L. Whatley Health Center, Tuscaloosa, AL

40 **Corresponding Author:** Christina Psaros, PhD, One Bowdoin Square, 7th Floor, Boston, MA,  
41

42 02114, USA, Phone: 617-726-7458; Fax: 617-724-3726; Email: cpsaros@mgh.harvard.edu.  
43

44 **Study Sponsor:** University of Alabama at Birmingham, School of Nursing, 1701 University  
45

46 Blvd, Birmingham, AL 35294  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Introduction:** African American women (AA), particularly those living in the southeastern United States (US), experience disproportionately high rates of HIV infection. Pre-exposure prophylaxis (PrEP) is a highly effective HIV prevention tool that may circumvent barriers to traditional HIV prevention tools, such as condom use; however, very little is known about how to improve PrEP access and uptake among AA women who may benefit from PrEP use. This project aims to understand how to increase PrEP access among AA women in the rural US South, which may ultimately affect HIV incidence in this population.

**Methods and Analysis:** The goal of the current study is to systematically adapt a patient-provider communication tool to increase PrEP uptake among AA women receiving care at a federally qualified health center (FQHC) in Alabama. We will use an iterative implementation process, by assessing the feasibility, acceptability, and preliminary impact of the tool on PrEP uptake, using a pilot pre-/post-intervention design (N=125). We will evaluate women's reasons for declining a referral to a PrEP provider, reasons for incomplete referrals, reasons for not initiating PrEP after a successful referral, and ongoing PrEP use at 3 and 12 months after PrEP initiation among our sample. The proposed work will significantly contribute to our understanding of factors impacting PrEP uptake and use among AA women, particularly in underserved areas in the Deep South that are heavily impacted by the HIV epidemic and experience worse HIV-related health outcomes relative to other areas in the US.

**Ethics and Dissemination:** This protocol has been approved by the Institutional Review Board (IRB) at University of Alabama at Birmingham (UAB; Birmingham, AL; protocol 300004276). Results will be disseminated through peer-reviewed manuscripts, reports, and local, national, and international presentations.

### Strengths and limitations of this study

- Application of an implementation science framework facilitates rapid implementation, evaluation, and modification of a novel patient-provider communication intervention to increase PrEP awareness and potential uptake for women in an U.S. region where HIV transmission remains comparatively high.
- Provides data on PrEP uptake and key social, behavioral, and cultural factors associated with PrEP uptake among African American women in the South, who remain under-represented in PrEP research despite being disproportionately affected by HIV.
- Expands knowledge base on PrEP attitudes and experiences among health care providers within a Federally Qualified Health Care Center (FQHC) in the South, where many women who may benefit from PrEP enter the health care system.
- Challenges and barriers identified by participants and providers throughout the adaptation process may include contextual, structural, and system-level factors that are beyond the scope of this communication intervention.

### Introduction

The Deep South region of the United States (US) bears the greatest burden of the HIV epidemic in the US, with rural counties disproportionately affected and underserved by both HIV care and prevention services.<sup>1,2</sup> Of the more than 1.1 million people living with HIV in the US in 2018, women accounted for nearly a quarter (23%) of all cases and a significant portion (19%) of new cases, with most new cases attributed to heterosexual contact (85%).<sup>3</sup> Despite representing just 13% of the US female population, African American (AA) women accounted for 55% of new HIV diagnoses among all women in the US in 2019.<sup>2</sup> In 2016, the rate of new HIV diagnoses among AA women was 15 times higher than that of White women,<sup>3</sup> and in

1  
2  
3 2018, HIV infection ranked in the top eight leading causes of death among AA women aged 20-  
4 44 in the US.<sup>4</sup> The elevated HIV risk profile among AA women in the South may reflect factors  
5  
6 unique to rural areas, such as the prevalence of small sexual networks resulting in cyclical HIV  
7  
8 transmission patterns,<sup>5</sup> in addition to barriers to HIV prevention rooted in structural racism such  
9  
10 as high incarceration rates among male AA populations, limited awareness of and access to  
11  
12 effective contraception and sexual health interventions, higher rates of concurrent partnerships  
13  
14 among AA men in AA women's sexual networks, and financial and transportation-related  
15  
16 barriers to accessing HIV/STI screening, prevention, and treatment.<sup>6-11</sup>  
17  
18  
19  
20  
21

22 Traditional HIV prevention efforts, such as abstinence-only education approaches that are  
23  
24 prevalent in the rural South, have been insufficient to control high rates of sexually transmitted  
25  
26 infections (STIs) and HIV infections. Abstinence-only education does not provide women with  
27  
28 comprehensive information critical for maintaining sexual health.<sup>12,13</sup> Moreover, interventions  
29  
30 promoting condom use, partner-based testing, and/or monogamous relationships are dependent  
31  
32 on behaviors of women's sexual partners and, therefore, may be outside each woman's direct  
33  
34 control. AA women experiencing financial challenges may be financially dependent on male  
35  
36 partners; they may also be experiencing intimate partner violence, further complicating their  
37  
38 ability to make independent sexual health decisions.<sup>14,15</sup> Given disproportionate diagnoses and  
39  
40 mortality among AA women, along with limitations to non-biomedical HIV prevention  
41  
42 methods, novel and more effective approaches to HIV prevention are necessary.  
43  
44  
45  
46

47 Biomedical HIV prevention tools, including pre-exposure prophylaxis (PrEP) are  
48  
49 promising as they hold the potential to minimize barriers to traditional means of HIV  
50  
51 prevention among groups who are persistently vulnerable to HIV infection. Oral PrEP has over  
52  
53 90% efficacy demonstrated across numerous trials, including cisgender women, but efficacy  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 depends on consistent daily adherence as prescribed.<sup>16</sup> Long-acting injectable PrEP is also  
4 highly efficacious for cisgender women and is now available for use in the U.S.<sup>17,18</sup> Although  
5 overall oral PrEP prescriptions in the US increased substantially between 2012 and 2017, PrEP  
6 uptake among AA women has remained low. While biomedical prevention efforts have  
7 historically focused on men who have sex with men (MSM), women have not received  
8 equitable attention reflective of the epidemiology.<sup>19</sup> Indeed, 94% of PrEP users in 2017 were  
9 male, indicating a substantial unmet need among PrEP-eligible women.<sup>18</sup> In 2016, only 11% of  
10 all PrEP users with available race/ethnicity data were from AA communities.<sup>20</sup>

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
Regardless of geographic location, most women in the US remain unaware of PrEP, and  
PrEP uptake among AA women remains low, particularly in rural areas of the US where  
women may have less access to healthcare and more limited knowledge of PrEP than women in  
urban areas.<sup>21</sup> In several studies, the majority of women participating in PrEP focus groups, as  
well as staff at health services organizations, were unfamiliar with PrEP as an HIV prevention  
tool and expressed concern about a broad lack of awareness within their communities; of the  
10% of women who had previously heard of PrEP, none were aware of its availability and  
efficacy for women.<sup>22,23</sup> However, AA women expressed being generally interested in using  
PrEP if available,<sup>24</sup> especially if recommended by a trusted health-care provider.<sup>25</sup>

Suboptimal patient-provider communication has been identified as a barrier to PrEP  
uptake among AA women,<sup>26</sup> as has limited provider knowledge of PrEP. Historically, the most  
common reported barriers to prescribing PrEP include a perceived lack of clinical training and  
experience in PrEP delivery, greater time investment to monitor patients on PrEP, and  
insufficient structural support from clinic sites.<sup>27</sup> In a 2022 survey of 359 health care providers  
across the US, 100% of respondents were aware of PrEP, about 97% reported willingness to

1  
2  
3 prescribe PrEP, and around 80% had prescribed PrEP;<sup>28</sup> however, these statistics varied by  
4  
5 region of practice and by race, with a higher number of providers prescribing PrEP in the West  
6  
7 and a disproportionate number of PrEP prescriptions provided to White individuals.<sup>28</sup> A recent  
8  
9 qualitative study among providers in Alabama indicated uncertainty about offering PrEP to AA  
10  
11 heterosexual, cis-gender adolescent or young adult females in the absence of transactional sex  
12  
13 or a known HIV positive partner.<sup>29</sup>  
14  
15

16  
17 Existing literature highlights numerous barriers to effective patient-provider  
18  
19 communication about sexual health, including time constraints, embarrassment or shame  
20  
21 surrounding these topics, patient confidentiality concerns, and both language and cultural  
22  
23 barriers.<sup>30-33</sup> Moreover, PrEP services are less routinely implemented in settings where many  
24  
25 patients who may benefit from PrEP use may receive care, such as Federally Qualified Health  
26  
27 Centers (FQHCs).<sup>34</sup> In rural areas and small metropolitan areas in particular, FQHCs offering a  
28  
29 variety of health services, ranging from primary care to family planning, have been central to  
30  
31 the provision of primary and preventive care to underserved populations.<sup>35</sup> Almost 6 million  
32  
33 women of reproductive age received care from FQHCs in 2012.<sup>36</sup> Of the 30 million patients  
34  
35 served by FQHCs in 2021, 65% were racial and/or ethnic minorities and 42% lived in rural  
36  
37 areas.<sup>37</sup> FQHCs are thus an important treatment setting for research geared toward increasing  
38  
39 PrEP access among AA women in the rural South.  
40  
41  
42  
43

#### 44 **Study Aims**

45  
46  
47 This paper describes the second phase of a two-phase study. The aim of the first phase  
48  
49 was to conduct qualitative interviews exploring preferences around patient-provider  
50  
51 communication about HIV and PrEP services to address the needs of AA women. Participants  
52  
53 (N=41) included FQHC patients – AA women who reported current and/or recent PrEP use  
54  
55  
56  
57  
58  
59  
60



(N=6) or had clinical indications for PrEP use (N=15) – as well as providers (N=20).<sup>38</sup>

The primary aims of this second phase of the study are: (1) to systematically adapt a patient-provider PrEP communication tool developed by the Centers for Disease Control and Prevention (CDC)<sup>39</sup> to increase PrEP uptake at an FQHC serving a small metropolitan area as well as rural Alabama, using an iterative implementation process, and (2) to assess the feasibility, acceptability, and preliminary impact of the patient-provider communication tool on PrEP uptake among AA women and their providers using a pilot pre-/post-intervention design (N=125).

## **Methods**

### ***Study Design***

During this second phase of the study, the qualitative data collected in the first phase has been used to adapt a patient-provider communication tool focusing on the first steps of the PrEP care cascade, notably identifying as a person who may benefit from PrEP use and being interested in using PrEP, among AA women receiving care at an FQHC in Alabama. For interested women, referrals to PrEP services within the health center will be facilitated. The protocol will be evaluated in real-time for acceptability and feasibility using both quantitative and qualitative data. The protocol will be iteratively updated until satisfactory procedures have been designed and simultaneously tested for preliminary impact on PrEP uptake. We anticipate conducting three waves of assessments (approximately every three to five months). Each wave will consist of 25-40 participants at one enrollment (clinic) site with a target total of N=125. This protocol will be tested for effectiveness, including cost-effectiveness, in a larger R01 cluster randomized implementation trial at primary care and reproductive health centers serving AA women vulnerable to HIV infection in the Deep South.

### ***Population and Setting***

Participants will include both patients (up to N=125) and healthcare providers (up to N=20) recruited from one FQHC in Alabama. The participating FQHC offers PrEP services, so all PrEP referrals are handled internally at the clinic. Participants will attend a total of two assessment visits (baseline and 3-month assessment) and an intervention visit following the baseline assessment.

### ***Eligibility Criteria***

Inclusion criteria for patients include: (1) self-identified cisgender women; (2) AA race; (3) age 18 or older; (4) not living with HIV according to self-report (5) any sex with male partners in past six months or anticipated sex in the next 6 months; (6) primary language English; and (7) willing and able to give informed consent. Inclusion criteria for healthcare providers includes: (1) fluency in English; (2) identifies as a physician, nurse practitioner, physician assistant, nurse, medical assistant, social worker/counselor or other potential PrEP service provider; and (3) willing and able to give informed consent. Potential participants may be excluded if the principal investigators determine, on a case-by-case basis, that their participation would be medically unsafe, complicate interpretation of study findings, or otherwise interfere with achieving study objectives.

### ***Theoretical Framework***

The Exploration, Preparation, Implementation, and Sustainment (EPIS) Implementation Framework<sup>40</sup> is a meta-theoretical framework that incorporates components from multiple evidence-based implementation process theories and provides a platform to guide intervention planning, adaptation and implementation (Figure 1). The EPIS has guided the development and evaluation of multiple implementation trials<sup>41,42</sup> and will be used as the overarching

1  
2  
3 methodological framework to guide intervention adaptation in this study. EPIS is segmented into  
4 four stages: *Exploration* (i.e., organization, provider, and client-level factors that identify  
5 potential barriers/facilitators for PrEP uptake); *Preparation* (i.e., adapting intervention to  
6 enhance PrEP uptake); *Implementation* (i.e., training, coaching, and active facilitation of patient-  
7 provider communication intervention); and *Sustainment* (i.e., PrEP uptake and adherence).  
8  
9

10  
11 Furthermore, the Dynamic Adaptation Process (DAP) framework, which is part of the  
12 *Preparation* and *Implementation* phases of EPIS, will be used in the adaptation of the patient-  
13 provider communication tool (Figure 1). The DAP provides direction for activities during each  
14 EPIS phase and a continuously iterative, data-informed approach to support intervention  
15 implementation.<sup>43</sup> Developed for the adaptation of evidence-based interventions (EBIs), it  
16 provides a model framework that includes adaptations tailored to specific subgroups. The DAP  
17 provides a process for pre-assessment, convening an “implementation resource team” to guide  
18 the implementation process, and use of audit and feedback data to help guide appropriate EBI  
19 adaptation.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34

### 35 ***Outcome Variables***

36  
37 Primary outcomes will include intervention feasibility, acceptability, and PrEP uptake.  
38 Secondary outcomes will include PrEP adherence; and clinic visit adherence. Psychosocial  
39 factors will also be measured to characterize the sample and assess potential mediating and  
40 moderating factors associated with the outcome measures. All measures and timing of  
41 assessments are provided in Table 1.  
42  
43  
44  
45  
46  
47  
48

49 **Feasibility.** We will measure the number of individuals screened, the number of eligible  
50 individuals enrolled, and the number of enrolled participants who initiate PrEP and adhere to  
51 their prescribed regimen. We will also track reasons for declining enrollment, prematurely  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 leaving the study, declining a referral, not attending a PrEP clinic visit, and/or discontinuing  
4 PrEP. Recruitment and scheduling strategies, participant contact, and feasibility of administering  
5 instruments (e.g., assessment duration), will be documented.  
6  
7

8  
9  
10 **Acceptability.** Acceptability will be assessed through in-depth, individual, qualitative exit  
11 interviews at the end of the study. Interviews will explore participants' experiences with and  
12 perceptions of the study, as well as their evaluations of the patient-provider communication tool  
13 to facilitate PrEP uptake. Patient and provider satisfaction with the intervention will be assessed  
14 via the Client Satisfaction Questionnaire (CSQ-8)<sup>44</sup> and the Behavioral Interventionist  
15 Satisfaction Survey (BISS).<sup>45</sup>  
16  
17

18  
19  
20 **PrEP Uptake.** PrEP uptake will be measured by calculating the ratio of patients initiating  
21 PrEP to the number of patients eligible for the study who enrolled and were referred to PrEP  
22 services.  
23  
24

25  
26  
27 **PrEP Adherence.** Self-report (i.e., Visual Analog Scale) will be used to assess patients'  
28 adherence to taking PrEP as prescribed, as is currently the standard practice in the participating  
29 clinics.<sup>46</sup> Reasons for discontinuing PrEP use, as applicable, will also be tracked. Participants  
30 will also be asked to rate, on a 6-point Likert scale, their ability to take all medications as  
31 prescribed.  
32  
33

34  
35  
36 **Clinic Visit Adherence.** Attendance at clinic visits will be defined as the number of PrEP  
37 visits attended divided by the number of visits scheduled. Adherence will be assessed at 3-month  
38 follow-up and 12-months via electronic medical record abstraction.  
39  
40

41  
42  
43 **Psychosocial Factors.** Psychosocial factors will include assessments of intimate partner  
44 violence, depression, anxiety, post-traumatic stress disorder (PTSD), sexual behaviors, HIV  
45  
46  
47  
48

1  
2  
3 transmission knowledge, substance use, social support, and spirituality/religiousness.  
4

### 5 ***Intervention Adaptation***

6  
7  
8 **Adaptation Activities.** Based on the formative evaluation in the first phase of this study,  
9  
10 involving qualitative interviews with patients and providers (i.e., *Exploration* phase), a first draft  
11  
12 of the patient-provider communication tool was produced. An adaptation plan as described by  
13  
14 Aarons and colleagues<sup>40</sup> was used to document changes (i.e., new activities and materials to be  
15  
16 included) to the protocol and reasons for such changes or additions. Given the minority status of  
17  
18 our target population, it was anticipated that cultural adaptations would include process and  
19  
20 content changes relevant to AA women vulnerable to HIV infection.<sup>64,65</sup> Adaptation was  
21  
22 considered on the patient, provider, and organizational levels as per the EPIS.  
23  
24  
25

26  
27 During the *Preparation* phase, an Implementation Resource Team (IRT) was convened to  
28  
29 review the first draft of the adapted patient-provider communication tool. The IRT was  
30  
31 comprised of experts in implementation science and PrEP delivery, representatives of the clinic  
32  
33 administration/staff (at both the FQHCs and the PrEP clinics), potential PrEP candidates and  
34  
35 PrEP users, providers, and members of the research team. A second draft of the adapted  
36  
37 communication tool integrated the recommendations made and measures added by the IRT,  
38  
39 again maintaining the core elements of the patient-provider communication tool and considering  
40  
41 the limitations and needs of the study sites.  
42  
43  
44

### 45 ***Intervention Implementation***

46  
47 **Provider Recruitment and Training.** Provider participants will be identified by the  
48  
49 partnering clinic's study research assistant (RA). The study RA will contact study research staff  
50  
51 on participating providers' behalf. Recruited providers will complete an informed consent form  
52  
53 and baseline assessment online. Links to the assessment battery will be sent to providers via  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 email by research team members. Signed consent forms and baseline assessment responses will  
4  
5 be directly entered into and stored in a secure Research Electronic Data Capture (REDCap)  
6  
7 database.  
8  
9

10         Enrolled providers will receive training in the use of the patient-provider communication  
11  
12 tool and best practices for prescribing PrEP. Training will be directed by health care practitioners  
13  
14 with extensive experience in PrEP prescribing, training providers in PrEP prescribing, and/or  
15  
16 managing PrEP-related logistics. Provider training will consist of two parts: first, providers will  
17  
18 watch two training videos, which will include an overview of PrEP basics and the study's  
19  
20 patient-provider communication tool; second, providers will participate in a live training session  
21  
22 (in-person or via virtual platform) with trainers, which will involve an interactive roleplay using  
23  
24 parts of the patient-provider communication tool, all of which has been piloted during phase I.  
25  
26 Additional trainings and preparation sessions may be held in-person at the clinic site or by phone  
27  
28 on an as-needed basis.  
29  
30  
31

32  
33         **Patient Recruitment.** Patient participants will be recruited in three ways: (1) the study RA  
34  
35 will pre-screen potential participants through their electronic medical records (EMR) and flag  
36  
37 any patients with upcoming clinic visits who meet study eligibility criteria; (2) flyers will be  
38  
39 posted in clinic waiting areas; and (3) health care providers at the participating clinic will  
40  
41 directly refer interested patients who may be eligible to participate in the study. If a patient is  
42  
43 recruited through EMR pre-screen, they will be formally screened by the study RA during their  
44  
45 routine clinic visit. If a patient is recruited via flyer or provider referral, they will either contact  
46  
47 the study RA by phone (using the phone number listed on the flyer) or may provide permission  
48  
49 to be contacted by the study RA directly, who will then screen the prospective participant by  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 phone. All individuals who meet inclusion criteria will be invited to complete the informed  
4  
5 consent process at the baseline visit (Figure 2).  
6

7  
8 **Informed Consent.** All participants will complete a baseline assessment visit either in-  
9  
10 person or by phone, in which they will review an informed consent form, which will include a  
11  
12 detailed explanation of all study procedures, information about potential risks and benefits of  
13  
14 participation, and contact information for the study team in the event of further questions. The  
15  
16 consent form will also state that participation is voluntary, that they can withdraw from the study  
17  
18 at any time, and that study participation is in no way related to their health care, including receipt  
19  
20 of PrEP services. Written or verbal consent will be obtained, and a copy of the signed consent  
21  
22 form will be provided to participants for their records.  
23  
24

25  
26 **Study Assessments and Intervention.** Enrolled patients will complete a quantitative  
27  
28 assessment during the baseline visit, administered via REDCap,<sup>66</sup> which will include  
29  
30 sociodemographics and measures of anxiety, depression, interpersonal violence, substance use,  
31  
32 PrEP awareness, sexual behaviors, PTSD as well as spiritual/emotional support. Patients will  
33  
34 then be scheduled to meet with a provider, who will use the newly adapted PrEP patient-provider  
35  
36 communication tool. Patients who are interested in receiving a referral for PrEP after completing  
37  
38 the intervention will be referred to the in-house PrEP clinic; this referral will include a “warm  
39  
40 hand-off” by a provider or PrEP navigator. Providers will document the visit in patients’  
41  
42 electronic health records per standard clinic practice. Referrals will be made if domestic or  
43  
44 intimate partner violence, and/or suicidal ideation are indicated in the risk assessment portion of  
45  
46 the quantitative baseline assessment.  
47  
48  
49

50  
51 Patients and providers at the local PrEP clinic will then jointly decide whether to initiate  
52  
53 PrEP after referral. Providers at the PrEP clinics will be responsible for all aspects of PrEP care,  
54  
55  
56  
57  
58  
59

1  
2  
3 including reviewing lab results, reinforcing educational messages around adherence and  
4 additional HIV/STI prevention options, and conducting patient examinations as needed,  
5  
6 consistent with their current PrEP delivery practices. Regardless of PrEP initiation, patients will  
7  
8 be scheduled for the 3-month follow-up study visit which will be conducted via phone call.  
9  
10 During implementation, quarterly feedback will be provided by the IRT (or more frequently if  
11  
12 needed), who will evaluate whether further adaptations are needed to the patient-provider  
13  
14 communication intervention. IRT members will be comprised of experts in implementation  
15  
16 science and PrEP delivery, representatives of the clinic administration and staff at local FQHCs,  
17  
18 potential PrEP candidates and users, providers, and members of the investigative team. Best  
19  
20 practices for intervention delivery process, type, and frequency of communication with AA  
21  
22 women vulnerable to HIV infection will also be assessed.  
23  
24  
25  
26  
27

28 **Remuneration.** Patients will be remunerated a total of \$100 for their participation and  
29  
30 transportation costs, independent of PrEP uptake. Providers will receive \$50 for their time and  
31  
32 1.5 credit hours of continuing education credit for their participation in the study training.  
33  
34

35 **Patient and Public Involvement.** Patient and PrEP healthcare provider involvement is  
36  
37 incorporated into the design and conduct of this implementation science trial. The  
38  
39 Implementation Resource Team described above is comprised of FQHC patients and PrEP  
40  
41 navigators/providers as well as research team members. The IRT guides and informs the  
42  
43 intervention design and implementation of the trial throughout the study, including the  
44  
45 interpretation and dissemination of results.  
46  
47  
48

#### 49 **Data Analyses**

50  
51 The feasibility, acceptability, and preliminary impact of this intervention will be assessed  
52  
53 among patients and providers using this pre-/post-intervention design. Quantitative data will be  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 analyzed using SPSS or R. Feasibility will be determined by evaluation of recruitment and  
4 retention, number of PrEP referrals, PrEP initiation, PrEP adherence, and clinic visit adherence.  
5  
6 Acceptability will be measured using in-depth, individual, qualitative exit interviews and  
7  
8 satisfaction surveys. Continuous feedback from participants and experts relevant to the  
9  
10 population and outcomes studied will assure feasibility, acceptability, and appropriateness of the  
11  
12 adapted intervention. Structural and content related changes of the intervention will be based on  
13  
14 the feedback provided by patients and providers.  
15  
16  
17  
18

19 Primary and secondary outcomes will be assessed by characterizing the sample using  
20  
21 descriptive statistics, computing confidence intervals on these measures, and exploring patient  
22  
23 and implementation characteristics as possible moderators of these outcomes in order to inform  
24  
25 the design of our future trial. Measures of effect size (e.g., Cohen's  $d$ , Cohen's  $r$ , Cramer's  $V$ ,  $R^2$ ,  
26  
27 etc.) will be used to determine the characteristics that individually appeared to be relevantly  
28  
29 associated with PrEP uptake and secondary outcomes in the sample.  
30  
31  
32

33 To examine impact of the protocol adaptation, we will use calendar quarter of entry in the  
34  
35 study as a possible moderator. Multivariable exploratory analyses will be conducted using non-  
36  
37 parametric methods<sup>67</sup> including penalized regression (LASSO) and Random Forest, to determine  
38  
39 if the sample data suggest a smaller set of relevant characteristics based on their cross-validated  
40  
41 predictive ability of each outcome. These data will be useful in tailoring our implementation  
42  
43 approach based on empirical observation. On *a priori* conceptual considerations, we expect age,  
44  
45 intimate partner violence and sexual risk behavior to be supported by the data as moderators of  
46  
47 PrEP uptake. In addition, exploratory mediation analyses will be conducted based on conceptual  
48  
49 considerations using the procedures outlined by Hayes.<sup>68</sup>  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Clinics' electronic medical record data be used to estimate PrEP uptake, based on the  
4 number of PrEP-eligible AA women who have been referred to PrEP in the three years pre- and  
5 post-implementation of the protocol (i.e., pre-/post-test design). Binomial logistic models  
6 (events/trials syntax) will be fitted with time-period and clinic as main effects to estimate the  
7 differences in uptake proportions between pre- and post-protocol time periods. To determine  
8 specific impact of the iterative process of protocol adaptation during the year of implementation,  
9 we will fit a logistic model for uptake with bi-monthly assessment wave number (3 waves) as  
10 categorical predictor. *A priori*, we expect a positive relationship between the assessment wave  
11 number and the odds of uptake, indicating that as the protocol became more refined during the  
12 year, PrEP uptake increased.

### 23 24 25 26 **Ethics and Dissemination**

27  
28 The study was a single-IRB (sIRB) at the University of Alabama at Birmingham (UAB)  
29 with reliant sites at Massachusetts General Hospital and Beth Israel Deaconess Medical Center.  
30 Ethics approval was obtained for all aspects of this study by the IRB at UAB (UAB; protocol  
31 300004276), where the work is being conducted. Study updates, preliminary findings, and final  
32 results will be disseminated through publication of manuscripts in peer-reviewed journals, as  
33 well as through reports to the National Institutes of Health, and through local, national, and  
34 international presentations at HIV-focused conferences and meetings.

## References

1. Centers for Disease Control and Prevention. HIV in the Southern United States Issue Brief. Centers for Disease Control and Prevention. Updated September 2019. Accessed September 2022. <https://www.cdc.gov/hiv/pdf/policies/cdc-hiv-in-the-south-issue-brief.pdf>
2. Centers for Disease Control and Prevention. Diagnoses of HIV Infection in the United States and Dependent Areas 2019: Special Focus Profiles. Centers for Disease Control and Prevention. Updated October 15, 2021. Accessed September 2022 <https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-32/content/special-focus-profiles.html#Women>
3. Kaiser Family Foundation. Women and HIV in the United States. KFF. Updated March 9, 2020. Accessed September 2022. <https://www.kff.org/hivaids/fact-sheet/women-and-hivaids-in-the-united-states/>
4. Centers for Disease Control and Prevention. Leading Causes of Death – Females – Non-Hispanic Black – United States, 2018. Centers for Disease Control and Prevention. Updated March 3, 2022. Accessed September 2022. <https://www.cdc.gov/women/lcod/2018/nonhispanic-black/index.htm>
5. Adimora AA, Schoenbach VJ, Doherty IA. HIV and African Americans in the southern United States: sexual networks and social context. *Sex Transm Dis*. 2006;33(7 Suppl):S39-45. doi: 10.1097/01.olq.0000228298.07826.68
6. Bowleg L, Malekzadeh AN, Mbaba M, et al. Ending the HIV Epidemic for All, Not Just Some: Structural Racism as a Fundamental but Overlooked Social-Structural Determinant of the U.S. HIV Epidemic. *Curr Opin HIV AIDS*. 2022;17(2):40–5. doi: 10.1097/COH.0000000000000724

- 1  
2  
3 7. Adimora AA, Schoenbach VJ, Martinson FE, et al. Heterosexually transmitted HIV infection  
4 among African Americans in North Carolina. *J Acquir Immune Defic Syndr*. 2006;41:616–23.  
5  
6 doi: 10.1097/01.qai.0000191382.62070.a5  
7
- 8 8. Adimora AA, Schoenbach VJ, Doherty IA. Concurrent sexual partnerships among men in the  
9  
10 United States. *Am J Public Health*. 2007;97(12):2230–7. doi: 10.2105/AJPH.2006.099069  
11  
12
- 13 9. Doherty IA, Schoenbach VJ, Adimora AA. Sexual mixing patterns and heterosexual HIV  
14  
15 transmission among African Americans in the southeastern United States. *J Acquir Immune*  
16  
17 *Defic Syndr*. 2009;52(1):114–20. doi: 10.1097/QAI.0b013e3181ab5e10  
18  
19
- 20 10. Harawa N AA. Incarceration, African Americans, and HIV: Advancing a research agenda. *J*  
21  
22 *Natl Med Assoc*. 2008;100(1):57-62. doi: 10.1016/s0027-9684(15)31175-5  
23  
24
- 25 11. Aaron E, Blum C, Seidman D, Hoyt MJ, Simone J, Sullivan M, et al. Optimizing Delivery of  
26  
27 HIV Preexposure Prophylaxis for Women in the United States. *AIDS Patient Care STDS*.  
28  
29 2018;32(1):16-23. doi: 10.1089/apc.2017.0201  
30  
31
- 32 12. Stanger-Hall KF, Hall DW. Abstinence-Only Education and Teen Pregnancy Rates: Why We  
33  
34 Need Comprehensive Sex Education in the U.S. *PLoS One*. 2011;6(10):e24658. doi:  
35  
36 10.1371/journal.pone.0024658  
37  
38
- 39 13. Jozkowski KN, Crawford BL. The Status of Reproductive and Sexual Health in Southern  
40  
41 USA: Policy Recommendations for Improving Health Outcomes. *Sex Res Soc Policy*.  
42  
43 2015;13:252–62. doi: <https://doi.org/10.1007/s13178-015-0208-7>  
44  
45
- 46 14. Cavanaugh CE, Hansen NB, Sullivan TP. HIV Sexual Risk Behavior Among Low-Income  
47  
48 Women Experiencing Intimate Partner Violence: The Role of Posttraumatic Stress Disorder.  
49  
50 *AIDS Behav*. 2010;14(2):318–27. doi: 10.1007/s10461-009-9623-1  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 15. Frew PM, Parker K, Vo L, et al. Socioecological factors influencing women's HIV risk in the  
4 United States: qualitative findings from the women's HIV SeroIncidence study (HPTN 064).  
5  
6 *BMC Public Health*. 2016;16:803. doi: <https://doi.org/10.1186/s12889-016-3364-7>  
7  
8  
9  
10 16. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in  
11 heterosexual men and women. *N Engl J Med*. 2012;367(5):399-410. doi:  
12  
13 10.1056/NEJMoa1108524  
14  
15  
16 17. World Health Organization. Trial results reveal that long-acting injectable cabotegravir as  
17 PrEP is highly effective in preventing HIV acquisition in women. World Health Organization.  
18 Updated November 9, 2020. Accessed September 2022. [https://www.who.int/news/item/09-11-](https://www.who.int/news/item/09-11-2020-trial-results-reveal-that-long-acting-injectable-cabotegravir-as-prep-is-highly-effective-in-preventing-hiv-acquisition-in-women)  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28 18. Delany-Moretlwe S, Hughes JP, Bock P, et al. Cabotegravir for the prevention of HIV-1 in  
29 women: results from HPTN 084, a phase 3, randomised clinical trial. *Lancet*.  
30  
31  
32 2022;399(10337):1779-89. doi: 10.1016/S0140-6736(22)00538-4  
33  
34  
35 19. HIV.gov. Impact on Racial and Ethnic Minorities. HIV.gov. Updated January 20, 2023.  
36 Accessed February 2023. [https://www.hiv.gov/hiv-basics/overview/data-and-trends/impact-on-](https://www.hiv.gov/hiv-basics/overview/data-and-trends/impact-on-racial-and-ethnic-minorities/)  
37  
38  
39  
40  
41  
42 20. Huang YA, Zhu W, Smith DK, et al. HIV Preexposure Prophylaxis, by Race and Ethnicity  
43 — United States, 2014–2016. *MMWR Morb Mortal Wkly Rep*. 2018;67:1147–50.  
44  
45  
46  
47  
48  
49 21. Sullivan PS, Mena L, Elopore L, et al. Implementation Strategies to Increase PrEP Uptake in  
50 the South. *Curr HIV/AIDS Rep*. 2019 6(4):259-69. doi: 10.1007/s11904-019-00447-4  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 22. Auerbach JD, Kinsky S, Brown G, et al. Knowledge, attitudes, and likelihood of pre-  
4 exposure prophylaxis (PrEP) use among US women at risk of acquiring HIV. *AIDS Patient Care*  
5 *STDS*. 2015;29(2):102-10. doi: 10.1089/apc.2014.0142  
6  
7  
8  
9  
10 23. Collier KL, Colarossi LG, Sanders K. Raising Awareness of Pre-Exposure Prophylaxis  
11 (PrEP) among Women in New York City: Community and Provider Perspectives. *J Health*  
12 *Commun*. 2017;22(3):183-9. doi: 10.1080/10810730.2016.1261969  
13  
14  
15  
16  
17 24. Sales JM, Steiner RJ, Brown JL, et al. PrEP Eligibility and Interest Among Clinic- and  
18 Community-Recruited Young Black Women in Atlanta, Georgia, USA. *Curr HIV Res*.  
19  
20 2018;16(3):250-5. doi: 10.2174/1570162X16666180731143756  
21  
22  
23  
24 25. Wingood GM, Dunkle K, Camp C, et al. Racial Differences and Correlates of Potential  
25 Adoption of Pre-exposure Prophylaxis (PrEP): Results of a National Survey. *J Acquir Immune*  
26 *Defic Syndr*. 2014;63(0 1):S95–S101. doi: 10.1097/QAI.0b013e3182920126  
27  
28  
29  
30  
31 26. Goparaju L, Praschan NC, Warren-Jeanpiere L, Experton LS, Young MA, Kassaye S.  
32 Stigma, Partners, Providers and Costs: Potential Barriers to PrEP Uptake among US Women. *J*  
33 *AIDS Clin Res*. 2017;8(9):730.  
34  
35  
36  
37  
38 27. Castel AD, Feaster DJ, Tang W, et al. Understanding HIV Care Provider Attitudes Regarding  
39 Intentions to Prescribe PrEP. *J Acquir Immune Defic Syndr*. 2016;70(5):520–8. doi:  
40 10.4172/2155-6113.1000730  
41  
42  
43  
44  
45 28. Rao S, Reed AE, Parchem B, et al. Optimizing Provider Preexposure Prophylaxis (PrEP)  
46 Training: A Cross-Sectional Analysis of Recommendations from Providers Across the PrEP  
47 Implementation Cascade. *AIDS Behav*. 2022;26:218–31. doi: 10.1007/s10461-021-03375-w  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 29. Pratt MC, Hill SV, Elopre L, et al. PrEP Prescription for Black Adolescent Girls and Young  
4 Women in Alabama: Findings from a Survey of Healthcare Providers. *J Int Assoc Provid AIDS*  
5 *Care*. 2022; 21:23259582221127936. doi: 10.1177/23259582221127936  
6  
7  
8  
9  
10 30. Hoopes AJ, Benson SK, Howard HB, et al. Adolescent Perspectives on Patient-Provider  
11 Sexual Health Communication: A Qualitative Study. *J Prim Care Community Health*.  
12 2017;8(4):332-7. doi: 10.1177/2150131917730210  
13  
14  
15  
16 31. Malta M, Todd CS, Stibich MA, et al. Patient-provider communication and reproductive  
17 health among HIV-positive women in Rio de Janeiro, Brazil. *Patient Educ Couns*.  
18 2010;81(3):476-82. doi: 10.1016/j.pec.2010.09.013  
19  
20  
21  
22  
23 32. Calabrese SK, Mayer KH. Stigma impedes HIV prevention by stifling patient-provider  
24 communication about U = U. *J Int AIDS Soc*. 2020;23(7):e25559. doi: 10.1002/jia2.25559  
25  
26  
27  
28 33. Flynn KE, Whicker D, Lin L, et al. Sexual Orientation and Patient-Provider Communication  
29 About Sexual Problems or Concerns Among US Adults. *J Gen Intern Med*. 2019;34(11):2505–  
30 11. doi: 10.1007/s11606-019-05300-3  
31  
32  
33  
34 34. Tookes H, Yao K, Chueng T, et al. Pre-exposure prophylaxis access in federally qualified  
35 health centers across 11 United States metropolitan statistical areas. *Int J STD AIDS*.  
36 2019;30(10):978-84. doi: 10.1177/0956462419855178  
37  
38  
39  
40  
41 35. National Association of Community Health Centers. Health Centers' Workforce: The  
42 Backbone of Our Country's Healthcare. National Association of Community Health Centers, Inc.  
43 Updated March 2022. Accessed September 2022. [https://www.nachc.org/wp-](https://www.nachc.org/wp-content/uploads/2022/02/P-I-Brief-2022.pdf)  
44 [content/uploads/2022/02/P-I-Brief-2022.pdf](https://www.nachc.org/wp-content/uploads/2022/02/P-I-Brief-2022.pdf)  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 36. Wood S, Beeson T, Bruen B, et al. Scope of family planning services available in Federally  
4 Qualified Health Centers. *Contraception*. 2014;89(2):85-90. doi:  
5  
6 10.1016/j.contraception.2013.09.015  
7  
8  
9  
10 37. National Association of Community Health Centers. America's Health Centers. National  
11 Association of Community Health Centers, Inc. Updated August 2022. Accessed September  
12 2022. [https://www.nachc.org/wp-content/uploads/2022/08/Americas-Health-Centers-](https://www.nachc.org/wp-content/uploads/2022/08/Americas-Health-Centers-2022_final.pdf)  
13  
14 2022\_final.pdf  
15  
16  
17  
18 38. Psaros C, Goodman G, Blyler A, et al. Barriers to expanding PrEP uptake among cisgender  
19 African American women in the South. Abstract presented at: 11th International AIDS Society  
20 (IAS) Conference on HIV Science; July 18-21, 2021; Virtual and Berlin, Germany. Accessed  
21  
22 September 2022. [https://www.natap.org/2021/IAS/IAS\\_59.htm](https://www.natap.org/2021/IAS/IAS_59.htm)  
23  
24  
25  
26  
27 39. Centers for Disease Control and Prevention. A Guide for the Healthcare Professional:  
28 Discussing Sexual Health with Your Patients. Centers for Disease Control and Prevention.  
29 Updated 2022. Accessed September 2022. [https://www.cdc.gov/hiv/pdf/clinicians/screening/cdc-](https://www.cdc.gov/hiv/pdf/clinicians/screening/cdc-hiv-php-discussing-sexual-health.pdf)  
30  
31 hiv-php-discussing-sexual-health.pdf.  
32  
33  
34 40. Aarons GA, Hurlburt M, Horwitz SM. Advancing a conceptual model of evidence-based  
35 practice implementation in public service sectors. *Adm Policy Ment Health*. 2011;38(1):4-23.  
36  
37 doi: 10.1007/s10488-010-0327-7  
38  
39  
40 41. Willging CE, Green AE, Ramos MM. Implementing school nursing strategies to reduce  
41 LGBTQ adolescent suicide: a randomized cluster trial study protocol. *Implementation Sci*.  
42 2016;11(145). doi: <https://doi.org/10.1186/s13012-016-0507-2>  
43  
44  
45  
46 42. Becan JE, Bartkowski JP, Knight DK, et al. A model for rigorously applying the Exploration,  
47 Preparation, Implementation, Sustainment (EPIS) framework in the design and measurement of a  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 large scale collaborative multi-site study. *Health Justice*. 2018;6(1):9. doi: 10.1186/s40352-018-  
4 0068-3  
5

6  
7 43. Aarons GA, Green AE, Palinkas LA, et al. Dynamic adaptation process to implement an  
8 evidence-based child maltreatment intervention. *Implementation Sci*. 2012;7(32). doi:  
9  
10  
11  
12 <https://doi.org/10.1186/1748-5908-7-32>  
13

14 44. Larsen DL, Attkisson CC, Hargreaves WA, et al. Assessment of client/patient satisfaction:  
15 development of a general scale. *Eval Program Plann*. 1979;2(3):197-207. doi: 10.1016/0149-  
16  
17 7189(79)90094-6  
18  
19

20 45. McLean KA. *Healthcare Provider Acceptability of a Behavioral Intervention to Promote*  
21  
22 *Adherence*. Master's thesis. University of Miami; 2013.  
23  
24  
25  
26 <https://scholarship.miami.edu/esploro/outputs/graduate/Healthcare-Provider-Acceptability-of-a->  
27  
28 Behavioral/991031447949202976  
29

30 46. Montgomery MC, Oldenburg CE, Nunn AS, et al. Adherence to Pre-Exposure Prophylaxis  
31 for HIV Prevention in a Clinical Setting. *PLoS One*. 2016;11(6):e0157742. doi:  
32  
33 10.1371/journal.pone.0157742  
34  
35

36 47. Lu M, Safren SA, Skolnik PR, et al. Optimal recall period and response task for self-reported  
37 HIV medication adherence. *AIDS Behav*. 2007;12(1):86-94. doi: 10.1007/s10461-007-9261-4  
38  
39

40 48. Laughon K, Renker P, Glass N, Parker B. Revision of the Abuse Assessment Screen to  
41 Address Nonlethal Strangulation. *JOGNN*. 2008;37(4):502-7. doi: <https://doi.org/10.1111/j.1552->  
42  
43 6909.2008.00268.x  
44  
45  
46

47 49. Radloff LS. The CES-D Scale: A Self-Report Depression Scale for Research in the General  
48 Population. *Applied Psychological Measurement*. 1977;1(3):385-401. doi:  
49  
50  
51  
52 <https://doi.org/10.1177/014662167700100306>  
53  
54  
55

- 1  
2  
3 50. Ironson G, Solomon GF, Balbin EG, et al. The Ironson-woods Spirituality/Religiousness  
4 Index is associated with long survival, health behaviors, less distress, and low cortisol in people  
5 with HIV/AIDS. *Ann Behav Med*. 2002;24(1):34-48. doi: 10.1207/S15324796ABM2401\_05  
6  
7  
8  
9  
10 51. Sherbourne CD, Stewart AL. The MOS social support survey. *Soc Sci Med*. 1991;32(6):705-  
11  
12 14. doi: 10.1016/0277-9536(91)90150-b  
13  
14  
15 52. McLellan AT, Luborsky L, Woody GE, et al. An improved diagnostic evaluation instrument  
16 for substance abuse patients. The Addiction Severity Index. *J Nerv Ment Dis*. 1980;168(1):26-33.  
17  
18 doi: 10.1097/00005053-198001000-00006  
19  
20  
21 53. Psaros C. *The BRiGHT Program: Building Resilience in HIV Together*. Clinicaltrials.gov;  
22 2018. Accessed September 2022. <https://clinicaltrials.gov/ct2/show/NCT03673098>  
23  
24  
25 54. Skapinakis P. Spielberger State-Trait Anxiety Inventory. In: Michalos AC (eds)  
26  
27 *Encyclopedia of Quality of Life and Well-Being Research*. Springer; 2014. doi:  
28  
29 [https://doi.org/10.1007/978-94-007-0753-5\\_2825](https://doi.org/10.1007/978-94-007-0753-5_2825)  
30  
31  
32 55. Napper LE, Branson CM, Fisher DG, et al. Assessing the validity of a single-item HIV risk  
33 stage-of-change measure. *J Drug Educ*. 2008;38(1):27-37. doi: 10.2190/DE.38.1.c  
34  
35  
36 56. Basta TB, Reece M, Wilson MG. Predictors of exercise stage of change among individuals  
37 living with HIV/AIDS. *Med Sci Sports Exerc*. 2008;40(9):1700-6. doi:  
38  
39 10.1249/MSS.0b013e318173f09e  
40  
41  
42 57. Taggart T, Liang Y, Pina P, Albritton T. Awareness of and willingness to use PrEP among  
43 Black and Latinx adolescents residing in higher prevalence areas in the United States. *PLoS*  
44  
45 *ONE*. 2020;15(7):e0234821. doi: <https://doi.org/10.1371/journal.pone.0234821>  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 58. Sikkema KJ, Heckman TG, Kelly JA, et al. HIV risk behaviors among women living in low-  
4 income, inner-city housing developments. *Am J Public Health*. 1996;86(1123–1128). doi:  
5  
6 10.2105/ajph.86.8\_pt\_1.1123  
7  
8  
9  
10 59. Ehrhart MG, Aarons GA, Farahnak LR. Assessing the organizational context for EBP  
11 implementation: the development and validity testing of the Implementation Climate Scale  
12 (ICS). *Implementation Sci*. 2014;9(157). doi: <https://doi.org/10.1186/s13012-014-0157-1>  
13  
14  
15  
16  
17 60. Hatz MHM, Sonnenschein T, Blankart CR. The PMA Scale: A Measure of Physicians'  
18 Motivation to Adopt Medical Devices. *Value Health*. 2017;20(4):533-41. doi:  
19  
20 10.1016/j.jval.2016.12.002  
21  
22  
23  
24 61. Heritage B, Pollock C, Roberts L. Validation of the Organizational Culture Assessment  
25 Instrument. *PLoS ONE*. 2014;9(3):e92879. doi: 10.1371/journal.pone.0092879  
26  
27  
28  
29 62. Institute of Behavioral Research. TCU Organizational Readiness for Change (ORC-  
30 D4). Texas Christian University, Institute of Behavioral Research; 2009. Accessed September  
31 2021. [https://ibr.tcu.edu/forms/organizational-staff-](https://ibr.tcu.edu/forms/organizational-staff-assessments/#:~:text=TCU%20Organizational%20Readiness%20for%20Change,individually%20C%20depending%20on%20assessment%20strategy)  
32  
33  
34  
35  
36  
37  
38  
39  
40 63. Stringer KL, Turan B, McCormick L, et al. HIV-Related Stigma Among Healthcare  
41 Providers in the Deep South. *AIDS Behav*. 2016;20(1):115-25. doi: 10.1007/s10461-015-1256-y  
42  
43  
44  
45 64. Marsiglia FF, Booth JM. Cultural Adaptation of Interventions in Real Practice Settings. *Res*  
46  
47  
48  
49  
50 65. Norton WE, Amico KR, Cornman DH, et al. An agenda for advancing the science of  
51 implementation of evidence-based HIV prevention interventions. *AIDS Behav*. 2009;13(3):424-  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 66. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)--a  
4 metadata-driven methodology and workflow process for providing translational research  
5 informatics support. *J Biomed Inform.* 2009;42(2):377-81. doi: 10.1016/j.jbi.2008.08.010  
6  
7

8  
9  
10 67. Efron B, Hastie T. *Computer Age Statistical Inference: Algorithms, Evidence, and Data*  
11 *Science*. Cambridge University Press; 2016.  
12

13  
14 68. Hayes A. *Introduction to Mediation, Moderation, and Conditional Process Analysis*. The  
15 Guilford Press; 2013.  
16

### 17 **Authors' Contributions**

18  
19 **C.P.** and **M.C.K.** conceived and designed the demonstration project and its protocol and directed  
20 protocol activities. **G.R.G.** drafted the protocol manuscript and designed several manuscript  
21 tables. **V.M.**, **C.O.**, **A.B.**, and **A.R.** contributed to drafting, editing, and finalizing the protocol  
22 manuscript and the design of the overall project protocol. **L.S.** planned and edited the statistical  
23 methods section of the manuscript. **M.C.** and **E.U.** advised on the protocol methods and provided  
24 comments on manuscript. **D.K.**, **L.E.**, **K.K.**, and **K.S.** advised on the structure and  
25 implementation of the protocol and provided comments on the protocol manuscript.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

37 **Funding Statement:** This work is supported by the National Institute of Mental Health (NIMH;  
38 grant number 5R34MH118044-03).  
39

40  
41  
42 **Competing interests:** None declared.  
43

44 **Word Count:** 3,666

45  
46 **Protocol issue date:** 07 Mar 2022

47  
48 **Protocol number:** 01  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 2.** WeExPAnd trial registration data

Data category	Information
<b>Primary registry and trial identifying number</b>	ClinicalTrials.gov NCT04373551
<b>Date of registry in primary registry</b>	May 4, 2020
<b>Secondary identifying numbers</b>	300003885, 1R34MH118044-01A1
<b>Source(s) of monetary or material support</b>	National Institute of Mental Health
<b>Primary sponsor</b>	National Institute of Mental Health
<b>Secondary sponsor</b>	N/a
<b>Contact for public queries</b>	Mirjam-Colette Kempf, PhD [mkempf@uab.edu]
<b>Contact for scientific queries</b>	Mirjam-Colette Kempf, PhD University of Alabama at Birmingham
<b>Public title</b>	PrEP Demonstration Project Among Women at Risk for HIV Infection
<b>Scientific title</b>	N/a
<b>Countries of recruitment</b>	United States
<b>Health condition(s) or problem(s) studied</b>	HIV-infection/AIDS
<b>Intervention(s)</b>	Behavioral: Cultural adaptation of a patient-provider communication tool
<b>Key inclusion and exclusion criteria</b>	Ages eligible for study: $\geq 18$ years Sexes eligible for study: cisgender female Gender-based eligibility: yes Accepts health volunteers: no
	Patients Inclusion criteria: African American cisgender women aged 18 years or older without HIV; report HIV risk and/or recent PrEP use; English-speaking
	Providers Inclusion criteria: Physicians, nurse practitioners, physician assistants, nurses, medical assistants, social workers/counselors or other potential/actual PrEP service providers; English-speaking
<b>Study type</b>	Interventional (Clinical Trial)
	Allocation: N/a
	Primary purpose: Health Services Research
	Phase: N/a
<b>Study start date</b>	April 14, 2020
<b>Target sample size</b>	125 participants
<b>Recruitment status</b>	Enrolling by invitation
<b>Primary outcome(s)</b>	PrEP uptake changes [Time Frame: baseline, 3 months, and 12 months] Intervention feasibility changes [Time Frame: baseline, 3 months, and 12 months] Intervention acceptability [Time Frame: Through study completion, an average of 12 months]
<b>Secondary outcome(s)</b>	PrEP adherence [Time Frame: 3 months and 12 months] Clinic visit adherence changes [Time Frame: 3 months and 12 months] Biological measures of HIV, STIs and pregnancy [Time Frame: baseline, 3 months, and 12 months]

## Appendix A

Page 1

# Patient Consent

Please complete the survey below.

Thank you!

---

Title of Research: We ExPAnd: PrEP Demonstration Project among Women at Risk  
for HIV Infection

UAB IRB Protocol #: IRB-300004276

Principal Investigator: Dr. Mirjam-Colette Kempf

Sponsor: National Institutes of Health (NIH)

**General Information** You are being asked to take part in a research study. This research study is voluntary, meaning you do not have to take part in it. The procedures, risks, and benefits are fully described further in the consent form.

**Purpose** The purpose of the study is to develop a better understanding of how to make HIV prevention medication, PrEP (known as pre-exposure prophylaxis which is action taken to prevent diseases before it happens), more accessible to African American women in Alabama.

**Duration & Visits** You will be in this study for 3 months. Visits will include a baseline visit, intervention visit, and 3-month follow-up visit.

**Overview of Procedures** This study will include a baseline assessment, a discussion with your provider using a patient-provider communication tool, and a 3-month follow-up assessment.

**Risks** The most common risk is feeling uncomfortable answering sexual health questions.

**Benefits** You may or may not benefit from participating in this study. However, this study may help us better understand how to optimize HIV prevention efforts and improve care in the future.

**Alternatives** The alternative is to not participate in this study.

---

**Purpose of the Research Study** We are asking you to take part in a research study of cis-gender women (individuals who were assigned the female sex at birth and identify as women) who are HIV-negative and potentially at risk for HIV. The purpose of the study is to develop a better understanding of how to make HIV prevention medication, PrEP (known as pre-exposure prophylaxis which is action taken to prevent diseases before it happens), more accessible to African American women in Alabama. It is hoped that the information gained from this study will help us understand the barriers and facilitators of PrEP use. You will receive information about PrEP during this study but will not receive PrEP medication as part of this research study. We anticipate recruitment of up to 250 participants from 2 clinics.

---

### Study Participation & Procedures if you agree to join the study:

You agree that study staff can contact you to schedule study visits. You will be asked to participate in a baseline assessment at your baseline visit. During this visit you will be asked to provide demographic information (5-10 mins) and complete baseline assessments (50-70 mins). You will discuss PrEP with your provider using a new patient-provider communication tool (10-15 mins). This tool will be used by your provider to discuss your sexual health and to help you make informed decision about your sexual health. You will participate in a 3-month follow-up assessment about your health and study participation (75-90 mins). Assessments conducted at baseline and 3-months will be completed in-person on a tablet. You do not have to agree to start a PrEP regimen in order to participate in this study. Baseline and 3-month assessments will be asking you questions about HIV stigma, abuse, depression, anxiety, Posttraumatic distress, addiction, religiousness, and sexual risk. Additionally, the 3-month assessment will include questions about your satisfaction in the study.

As mentioned, during the baseline visit, you will also be asked to complete a few demographic questions. These questions will include contact information so that the study staff can contact you regarding appointments. These questions will also include information regarding insurance coverage, annual income, and the location of your place of residence. It is important to understand exactly what this information will be used for so that you can make an informed decision to participate in this portion of the study.

We are asking you to give UAB researchers the authorization to use your address so that we can examine how you and your neighborhood influence your health and wellness. A member of the study staff will match your address to a geographic area called a census block group (CBG), which is large enough so that your exact address cannot be determined. CBG's are used by the US Census to report on demographic characteristics of entire communities. The community demographic data - and not your address- will be used by researchers to help them better understand how neighborhood and community factors relate to health and wellness. This process is called spatial mapping. Your actual address will not be reported, published or shared with anyone else.

You can choose to opt-out of the spatial mapping portion of the study. You can still participate in the study if you choose to opt-out of this part of the study. If you choose to opt-out of this part of the study, the study staff will make a note of this in your participant file.

- I agree to allow spatial mapping  
 I do not agree to allow spatial mapping

---

#### Additional Information

Your de-identified private information may be used for future research studies or distributed to another researcher for future research studies without additional informed consent.

---

#### Risks and Discomforts

It is unlikely that you will be at risk for physical harm as a result of your study participation. You may find some of the questions asked in the assessments emotionally upsetting. You may decline to answer questions which upset you.

---

#### Benefits

You may or may not benefit directly from taking part in this study. However, this study may help us better understand how to optimize HIV prevention efforts and improve care in the future.

---

#### Alternatives

The alternative is to not participate in this study.

---

#### Confidentiality and Authorization to Use and Disclose Information for Research Purposes

Federal regulations give you certain rights related to your health information. These include the right to know who will be able to get the information and why they may be able to get it. The study doctor must get your authorization (permission) to use or give out any health information that might identify you.

All participants are assigned a study identification number. In this study, information with your name is stored separately from information that we collect for the study, which will be stored with a study identification number. The information with your name is used for tracking purposes and for contacting you or others you have given us permission to contact. Only study staff who are trained in confidentiality and research ethics, are allowed access to this information.

---

#### What protected health information may be used and/or given to others?

All medical information, including but not limited to information and/or records of any diagnosis or treatment of disease or condition, which may include sexually transmitted diseases (e.g., HIV, etc.) or communicable diseases, drug/alcohol dependency, etc.; all personal identifiers, including but not limited to your name, social security number, medical record number, date of birth, dates of service, etc.; any past, present, and future history, examinations, laboratory results, imaging studies and reports and treatments of any kind, including but not limited to drug/alcohol treatment, psychiatric/psychological treatment; financial/billing information, including but not limited to copies of your medical bills; any other information related to or collected for use in the research study, regardless of whether the information was collected for research or non-research (e.g., treatment) purposes; records about any study drug you received or about study devices used; and consent forms from past studies that might be in your medical record.

A description of this clinical trial will be available on [www.ClinicalTrials.gov](http://www.ClinicalTrials.gov), as required by U.S. Law. This website will not include information that can identify you. At most, the website will include a summary of the results. You can search this website at any time.

---

Who may use and give out this information?

Information about your health may be used and given to others by the study doctor and staff. They might see the research information during and after the study.

---

Who might get this information?

All individuals/entities listed in the informed consent document(s), including but not limited to, the physicians, nurses and staff and others performing services related to the research (whether at UAB or elsewhere). Your information may also be given to the sponsor of this research. "Sponsor" includes any persons or companies that are working for or with the sponsor, or are owned by the sponsor, or are providing support to the sponsor (e.g., contract research organization).

Information about you and your health which might identify you may be given to:

The Office for Human Research Protections (OHRP)      The U.S. Food and Drug Administration (FDA)  
 Department of Health and Human Services (DHHS) agencies      Governmental agencies in other countries  
 Governmental agencies to whom certain diseases (reportable diseases) must be reported      The University of  
 Alabama at Birmingham - the physicians, nurses and staff working on the research study (whether at UAB or  
 elsewhere); the UAB IRB and its staff      The billing offices of UAB and UAB Health Systems affiliates and/or  
 Children's of Alabama and its billing agents

---

Why will this information be used and/or given to others?

Information about you and your health that might identify you may be given to others to carry out the research study. The sponsor will analyze and evaluate the results of the study. In addition, people from the sponsor and its consultants will be visiting the research site. They will follow how the study is done, and they will be reviewing your information for this purpose.

This research is covered by a Certificate of Confidentiality from the National Institutes of Health. The researchers with this Certificate may not disclose or use information, documents, or biospecimens that may identify you in any federal, state, or local civil, criminal, administrative, legislative, or other action, suit, or proceeding, or be used as evidence, for example, if there is a court subpoena, unless you have consented for this use. Information, documents, or biospecimens protected by this Certificate cannot be disclosed to anyone else who is not connected with the research except, if there is a federal, state, or local law that requires disclosure (such as to report child abuse or communicable diseases but not for federal, state, or local civil, criminal, administrative, legislative, or other proceedings, see below); if you have consented to the disclosure, including for your medical treatment; or if it is used for other scientific research, as allowed by federal regulations protecting research subjects.

The Certificate cannot be used to refuse a request for information from personnel of the United States federal or state government agency sponsoring the project that is needed for auditing or program evaluation by the NIH which is funding this project or for information that must be disclosed in order to meet the requirements of the federal Food and Drug Administration (FDA). You should understand that a Certificate of Confidentiality does not prevent you from voluntarily releasing information about yourself or your involvement in this research. If you want your research information released to an insurer, medical care provider, or any other person not connected with the research, you must provide consent to allow the researchers to release it.

The Certificate of Confidentiality will not be used to prevent disclosure as required by federal, state, or local law of such as child abuse and neglect, or harm to self or others.

The Certificate of Confidentiality will not be used to prevent disclosure for any purpose you have consented to in this informed consent document.

Information obtained during the course of the study which, in the opinion of the investigator(s), suggests that you may be at significant risk of harm to yourself or others will be reportable to a third party in the interest of protecting the rights and welfare of those at potential risk.



---

What if I decide not to give permission to use and give out my health information?

1  
2  
3 By signing this consent form, you are giving permission to use and give out the health information listed above for  
4 the purposes described above. If you refuse to give permission, you will not be able to be in this research.

---

5  
6 May I review or copy the information obtained from me or created about me?

7  
8  
9 You have the right to review and copy your health information. However, if you decide to be in this study and sign  
10 this permission form, you will not be allowed to look at or copy your information until after the research is completed.

---

11  
12 May I withdraw or revoke (cancel) my permission?

13  
14 Yes, but this permission will not stop automatically. The use of your personal health information will continue until  
15 you cancel your permission.

16  
17  
18 You may withdraw or take away your permission to use and disclose your health information at any time. You do this  
19 by sending written notice to the study doctor. If you withdraw your permission, you will not be able to continue being  
20 in this study.

21  
22  
23 When you withdraw your permission, no new health information which might identify you will be gathered after that  
24 date. Information that has already been gathered may still be used and given to others. This would be done if it were  
25 necessary for the research to be reliable.

---

26  
27 Is my health information protected after it has been given to others?

28  
29  
30 If you give permission to give your identifiable health information to a person or business, the information may no  
31 longer be protected. There is a risk that your information will be released to others. Including others outside of UAB,  
32 without your permission.

---

33  
34 Voluntary Participation and Withdrawal

35  
36 Whether or not you take part in this study is your choice. There will be no penalty if you decide not to be in it. If you  
37 decide not to be in the study, you will not lose any benefits you are otherwise owed.

38  
39  
40 You are free to withdraw from this study at any time. Your choice to leave the study will not affect your relationship  
41 with this institution. Contact [REDACTED] or [REDACTED] if you want to withdraw  
42 from the study.

43  
44  
45 You may be removed from the study without your consent if the sponsor ends the study or if you are not following  
46 the study rules.

---

47  
48 Cost of Participation

49  
50 There will be no cost to you for taking part in this study.

---

51  
52 Payment for Participation

53  
54 You will be paid \$100 if you complete each stage of this study: \$30 baseline, \$30 intervention visit, and \$40 for  
55 3-month follow-up. If you withdraw from the study you are only paid for the portions you completed. Ask the study  
56 staff about the method of payment that will be used for this study (e.g., check, cash, gift card, direct deposit).

---

## New Findings

You will be told by the study doctor or the study staff if new information becomes available that might affect your choice to stay in the study.

---

### Optional

#### Future Research Use of Identifiable Private Information and/or Identifiable Biospecimens

We would like your permission to keep your private information (data containing personal information) collected in this study for future research. The future research may be similar to this study or may be completely different. Your private information will be stored indefinitely or until used.

You can take part in this study even if you decide not to let us keep your identifiable private information for future research.

If you give us permission now to keep your identifiable private information, you can change your mind later and ask us to destroy it. However, once we have analyzed your private information, we may not be able to take it out of our future research.

We may share your identifiable private information, so that others can use it in their research. Their research may be similar to this study or may be completely different. Once we have shared your identifiable private information with other researchers, we will not be able to get it back.

Future research use of your identifiable private information will be conducted in compliance with applicable regulatory requirements.

You will not find out the results of the future research. Allowing us to do future research on your identifiable private information will not benefit you directly.

Select your choice below:

- I agree to allow my identifiable private information to be kept and used for future research on HIV prevention studies
- I do not agree to allow my identifiable private information to be kept and used for future research.
- 

### Questions

If you have any questions, concerns, or complaints about the research or a research-related injury including available treatments, please contact the study doctor. You may contact Dr. Mirjam-Colette Kempf at [REDACTED]

If you have questions about your rights as a research participant, or concerns or complaints about the research, you may contact the UAB Office of the IRB (OIRB) at (205) 934-3789 or toll free at 1-855-860-3789. Regular hours for the OIRB are 8:00 a.m. to 5:00 p.m. CT, Monday through Friday.

---

### Legal Rights

You are not waiving any of your legal rights by signing this consent form.

---

### Signatures

Your signature below indicates that you have read (or been read) the information provided above and agree to participate in this study. You will receive a copy of this signed consent form.

---


Full name of the participant \_\_\_\_\_

---

Signature of Participant \_\_\_\_\_

---


**Figure 1: Measurement framework of EPIS stages**



**Table 1.** Measures to be Administered at Each Assessment Visit.

Patients	BL	PT	3M	12M
<b>Recruitment:</b> Number screened; number of eligible individuals enrolled; reasons for declining enrollment or leaving study; participant contact throughout study; recruitment/scheduling strategies; feasibility of administering instruments/questions	X		X	
<b>PrEP referral:</b> Number of patients referred; number of patients accepting referral; reasons for declining referral; reasons for unsuccessful or incomplete referral		X	X	X
<b>PrEP uptake:</b> Ratio of patients initiating PrEP to the number eligible patients screened and referred (measured throughout)			X	X
<b>PrEP adherence:</b> Self-report via Visual Analog Scale <sup>47</sup> ; reasons for discontinuing PrEP	X		X	
<b>Clinic visit adherence:</b> Calculated as PrEP visits adhered to divided by PrEP visits scheduled			X	X
<b>Satisfaction with intervention:</b> Client Satisfaction Questionnaire (CSQ-8) <sup>44</sup>		X		
<b>Perceptions of study and evaluation of intervention:</b> Qualitative interview			X	
<b>Intimate partner violence:</b> Abuse Assessment Screen (AAS) <sup>48</sup>	X		X	
<b>Depression:</b> Center for Epidemiologic Studies Depression (CES-D) <sup>49</sup>	X		X	
<b>Spiritual support:</b> Ironson-Woods Spirituality/Religiousness (SR) <sup>50</sup>	X			
<b>Social Support:</b> Medical Outcomes Study (MOS) Social Support Survey <sup>51</sup>	X			
<b>Substance use:</b> Addiction Severity Index-Lite (ASI-Lite) <sup>52</sup>	X		X	
<b>Trauma experience:</b> Adapted from items within Project BRiGHT <sup>53</sup>	X		X	
<b>Anxiety:</b> State-Trait Anxiety Inventory State Form (STAI-S) <sup>54</sup>	X		X	
<b>Identification with organization: Items drafted by study team</b>	X			
<b>Stage of change:</b> Adapted from Stage of Change measures <sup>55,56</sup>	X	X	X	
<b>PrEP knowledge and experience:</b> Adapted from PrEP Awareness and Willingness <sup>57</sup>	X			
<b>HIV transmission knowledge:</b> Adapted from the HIV Risk Knowledge Test <sup>58</sup>	X		X	
<b>Sexual behavior:</b> Number of sexual partners; alcohol/drug use before sex; vaginal/anal sex; knowledge of partners' HIV status; condom use	X		X	
<b>Reflecting and evaluating:</b> Quantitative and qualitative feedback about progress and quality of implementation, accompanied with regular personal and team debriefing about progress and experience.				Continuous
<b>Proposed intervention modifications:</b> Both structural and didactic				Continuous
Providers	BL	PT	3M	12M
<b>Sociodemographics:</b> Age, race, ethnicity, education, clinic position	X			
<b>Implementation readiness:</b> Adapted from the Implementation Climate Scale (ICS) <sup>59</sup>	X			
<b>Dispositional innovativeness:</b> Physician-Motivation-Adoption (PMA) <sup>60</sup>	X			
<b>Culture:</b> Organizational Culture Assessment Instrument (OCAI) <sup>61</sup>	X			
<b>Patient needs and clinic resources:</b> Adapted subscales from Texas Christian University Organizational Readiness for Change Scale (TCU-ORC-D4) <sup>62</sup>	X			
<b>Stigma:</b> Adapted from the Attitude Toward People Living with HIV Scale <sup>63</sup>	X			
<b>Satisfaction with intervention:</b> Behavioral Interventionist Satisfaction Survey (BISS) <sup>45</sup> (12M only) and Short Survey (PT only)		X		X
<b>Identification with organization:</b> Qualitative interview				X
<b>Stage of change:</b> Qualitative interview				X
<b>Perceptions of study and evaluation of intervention:</b> Qualitative interview				X
<b>Reflecting and evaluating:</b> Quantitative and qualitative feedback about progress and quality of implementation, accompanied with regular personal and team debriefing about progress and experience.				X
<b>Proposed intervention modifications:</b> Both structural and didactic				Continuous

**Note:** BL = baseline; PT = post-treatment; 3M = 3-month assessment visit; 12M = 12-month data abstraction from EMR (patients) or assessment visit (provider)



# Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D. SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials. *BMJ*. 2013;346:e7586

	Reporting Item	Page Number
<b>Administrative information</b>		
Title	<a href="#">#1</a> Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	<a href="#">#2a</a> Trial identifier and registry name. If not yet registered, name of intended registry	28
Trial registration: data set	<a href="#">#2b</a> All items from the World Health Organization Trial Registration Data Set	28
Protocol version	<a href="#">#3</a> Date and version identifier	27
Funding	<a href="#">#4</a> Sources and types of financial, material, and other support	27
Roles and responsibilities: contributorship	<a href="#">#5a</a> Names, affiliations, and roles of protocol contributors	1 & 27

1	Roles and	<a href="#">#5b</a>	Name and contact information for the trial	1
2	responsibilities:		sponsor	
3	sponsor contact			
4	information			
5				
6				
7				
8	Roles and	<a href="#">#5c</a>	Role of study sponsor and funders, if	n/a; This funding source and
9	responsibilities:		any, in study design; collection,	sponsor had no role in the
10	sponsor and funder		management, analysis, and interpretation	design of this study and will
11			of data; writing of the report; and the	not have any role during its
12			decision to submit the report for	execution, analyses,
13			publication, including whether they will	interpretation of the data, or
14			have ultimate authority over any of these	decision to submit results.
15			activities	
16				
17				
18				
19				
20				
21	Roles and	<a href="#">#5d</a>	Composition, roles, and responsibilities	n/a; IRB has designated the
22	responsibilities:		of the coordinating centre, steering	study minimal risk; all
23	committees		committee, endpoint adjudication	aspects of the trial are
24			committee, data management team, and	overseen by the co-PIs and
25			other individuals or groups overseeing	research team
26			the trial, if applicable (see Item 21a for	
27			data monitoring committee)	
28				
29				
30				
31				
32	<b>Introduction</b>			
33				
34	Background and	<a href="#">#6a</a>	Description of research question and	3
35	rationale		justification for undertaking the trial,	
36			including summary of relevant studies	
37			(published and unpublished) examining	
38			benefits and harms for each intervention	
39				
40				
41				
42	Background and	<a href="#">#6b</a>	Explanation for choice of comparators	n/a; Single Group
43	rationale: choice of			Assignment
44	comparators			
45				
46				
47				
48	Objectives	<a href="#">#7</a>	Specific objectives or hypotheses	6
49				
50	Trial design	<a href="#">#8</a>	Description of trial design including type	7
51			of trial (eg, parallel group, crossover,	
52			factorial, single group), allocation ratio,	
53			and framework (eg, superiority,	
54			equivalence, non-inferiority, exploratory)	
55				
56				
57				
58	<b>Methods:</b>			
59				
60				

1 **Participants,**  
2 **interventions, and**  
3 **outcomes**  
4

5 Study setting	<a href="#">#9</a>	6 Description of study settings (eg, 7 community clinic, academic hospital) and 8 list of countries where data will be 9 collected. Reference to where list of 10 study sites can be obtained	8
13 Eligibility criteria	<a href="#">#10</a>	14 Inclusion and exclusion criteria for 15 participants. If applicable, eligibility 16 criteria for study centres and individuals 17 who will perform the interventions (eg, 18 surgeons, psychotherapists)	8
22 Interventions: 23 description	<a href="#">#11a</a>	24 Interventions for each group with 25 sufficient detail to allow replication, 26 including how and when they will be 27 administered	14
29 Interventions: 30 modifications	<a href="#">#11b</a>	31 Criteria for discontinuing or modifying 32 allocated interventions for a given trial 33 participant (eg, drug dose change in 34 response to harms, participant request, 35 or improving / worsening disease)	14
37 Interventions: 38 adherence	<a href="#">#11c</a>	39 Strategies to improve adherence to 40 intervention protocols, and any 41 procedures for monitoring adherence (eg, 42 drug tablet return; laboratory tests)	15
44 Interventions: 45 concomitant care	<a href="#">#11d</a>	46 Relevant concomitant care and 47 interventions that are permitted or 48 prohibited during the trial	n/a; No restrictions or specific allowances made on any health-related care or interventions during study participation.
52 Outcomes	<a href="#">#12</a>	53 Primary, secondary, and other outcomes, 54 including the specific measurement 55 variable (eg, systolic blood pressure), 56 analysis metric (eg, change from 57 baseline, final value, time to event),	9



method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended

8 9 10 11 12 13 14 15	Participant timeline	<a href="#">#13</a>	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	14
16 17 18 19 20 21 22 23 24	Sample size	<a href="#">#14</a>	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	7
25 26 27 28 29	Recruitment	<a href="#">#15</a>	Strategies for achieving adequate participant enrolment to reach target sample size	13

## Methods:

### Assignment of interventions (for controlled trials)

37 38 39 40 41 42 43 44 45 46 47 48 49 50	Allocation: sequence generation	<a href="#">#16a</a>	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	n/a; This study uses a single group assignment with no randomization or masking.
51 52 53 54 55 56 57 58 59 60	Allocation concealment mechanism	<a href="#">#16b</a>	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until	n/a; This study uses a single group assignment with no randomization or masking.

interventions are assigned

1  
2  
3 Allocation: [#16c](#) Who will generate the allocation n/a; This study uses a single  
4 implementation sequence, who will enrol participants, group assignment with no  
5 and who will assign participants to randomization or masking.  
6 interventions  
7

8  
9 Blinding (masking) [#17a](#) Who will be blinded after assignment to n/a; This study uses a single  
10 interventions (eg, trial participants, care group assignment with no  
11 providers, outcome assessors, data randomization or masking.  
12 analysts), and how  
13  
14

15  
16 Blinding (masking): [#17b](#) If blinded, circumstances under which n/a; This study uses a single  
17 emergency unblinding is permissible, and procedure group assignment with no  
18 unblinding for revealing a participant's allocated randomization or masking.  
19 intervention during the trial  
20  
21

22  
23 **Methods: Data**  
24 **collection,**  
25 **management, and**  
26 **analysis**  
27  
28

29  
30 Data collection plan [#18a](#) Plans for assessment and collection of 10  
31 outcome, baseline, and other trial data,  
32 including any related processes to  
33 promote data quality (eg, duplicate  
34 measurements, training of assessors)  
35 and a description of study instruments  
36 (eg, questionnaires, laboratory tests)  
37 along with their reliability and validity, if  
38 known. Reference to where data  
39 collection forms can be found, if not in  
40 the protocol  
41  
42  
43  
44  
45  
46

47 Data collection [#18b](#) Plans to promote participant retention 15  
48 plan: retention and complete follow-up, including list of  
49 any outcome data to be collected for  
50 participants who discontinue or deviate  
51 from intervention protocols  
52  
53  
54

55 Data management [#19](#) Plans for data entry, coding, security, and 14  
56 storage, including any related processes  
57 to promote data quality (eg, double data  
58  
59

entry; range checks for data values).  
Reference to where details of data management procedures can be found, if not in the protocol

1			
2			
3			
4			
5			
6			
7	Statistics:	<a href="#">#20a</a>	15
8	outcomes	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	
9			
10			
11			
12			
13			
14			
15	Statistics:	<a href="#">#20b</a>	16
16	additional analyses	Methods for any additional analyses (eg, subgroup and adjusted analyses)	
17			
18			
19	Statistics: analysis	<a href="#">#20c</a>	16
20	population and	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	
21	missing data		
22			
23			
24			
25			
26			
27	<b>Methods:</b>		
28	<b>Monitoring</b>		
29			
30			
31	Data monitoring:	<a href="#">#21a</a>	n/a; IRB designated study
32	formal committee	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	minimal risk; all data monitoring occurs internally by the co-principle investigators.
33			
34			
35			
36			
37			
38			
39			
40			
41			
42			
43			
44			
45	Data monitoring:	<a href="#">#21b</a>	n/a; Plans for interim
46	interim analysis	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	analyses are detailed in the IRB-approved data safety monitoring plan and are not described fully in the protocol manuscript.
47			
48			
49			
50			
51			
52			
53			
54			
55	Harms	<a href="#">#22</a>	n/a; Plans for adverse
56		Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events	events are detailed in the IRB-approved data safety
57			
58			
59			
60			

		and other unintended effects of trial interventions or trial conduct	monitoring plan and are not described fully in the protocol manuscript.
1			
2			
3			
4			
5	Auditing	<a href="#">#23</a> Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	n/a; Plans for trial conduct audits are detailed in the IRB-approved data safety monitoring plan and are not described fully in the protocol manuscript.
6			
7			
8			
9			
10			
11			
12			
13			
14			
15	<b>Ethics and dissemination</b>		
16			
17			
18			
19	Research ethics approval	<a href="#">#24</a> Plans for seeking research ethics committee / institutional review board (REC / IRB) approval	17
20			
21			
22			
23			
24	Protocol amendments	<a href="#">#25</a> Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC / IRBs, trial participants, trial registries, journals, regulators)	15
25			
26			
27			
28			
29			
30			
31			
32			
33			
34	Consent or assent	<a href="#">#26a</a> Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	14
35			
36			
37			
38			
39			
40			
41	Consent or assent: ancillary studies	<a href="#">#26b</a> Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	29
42			
43			
44			
45			
46			
47			
48	Confidentiality	<a href="#">#27</a> How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	17; IRB approval has been obtained for all aspects of the study, including the collection and protection of participant confidentiality and personal information
49			
50			
51			
52			
53			
54			
55			
56			
57			
58	Declaration of	<a href="#">#28</a> Financial and other competing interests	27
59			
60			

1	interests		for principal investigators for the overall trial and each study site	
2				
3				
4	Data access	<a href="#">#29</a>	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	n/a; Data access enumerated in the IRB-approved Data Safety Monitoring Plan and protocol
5				
6				
7				
8				
9				
10				
11	Ancillary and post trial care	<a href="#">#30</a>	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	n/a; This trial has been designated as minimal risk by the UAB IRB.
12				
13				
14				
15				
16	Dissemination policy: trial results	<a href="#">#31a</a>	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	17
17				
18				
19				
20				
21				
22				
23				
24				
25				
26				
27	Dissemination policy: authorship	<a href="#">#31b</a>	Authorship eligibility guidelines and any intended use of professional writers	n/a; Author contributions detailed on page 27 and no professional writers were used
28				
29				
30				
31				
32				
33				
34	Dissemination policy: reproducible research	<a href="#">#31c</a>	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	n/a; No current plans exist for granting public access to full protocol, participant dataset, or statistical code.
35				
36				
37				
38				
39				
40				
41	<b>Appendices</b>			
42				
43	Informed consent materials	<a href="#">#32</a>	Model consent form and other related documentation given to participants and authorised surrogates	29
44				
45				
46				
47				
48				
49	Biological specimens	<a href="#">#33</a>	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	n/a; This study collects no biological specimen.
50				
51				
52				
53				
54				
55				
56				
57	Notes:			
58				
59				
60				

- 1 • 5c: n/a; This funding source and sponsor had no role in the design of this study and will not have  
2 any role during its execution, analyses, interpretation of the data, or decision to submit results.  
3
- 4 • 5d: n/a; IRB has designated the study minimal risk; all aspects of the trial are overseen by the co-  
5 PIs and research team  
6
- 7 • 6b: n/a; Single Group Assignment  
8
- 9 • 11d: n/a; no restrictions or specific allowances made on any health-related care or interventions  
10 during study participation.  
11
- 12 • 16a: n/a; This study uses a single group assignment with no randomization or masking.  
13
- 14 • 16b: n/a; This study uses a single group assignment with no randomization or masking.  
15
- 16 • 16c: n/a; This study uses a single group assignment with no randomization or masking.  
17
- 18 • 17a: n/a; This study uses a single group assignment with no randomization or masking.  
19
- 20 • 17b: n/a; This study uses a single group assignment with no randomization or masking.  
21
- 22 • 21a: n/a; IRB designated study minimal risk; all data monitoring occurs internally by the co-  
23 principle investigators.  
24
- 25 • 21b: n/a; Plans for interim analyses are detailed in the IRB-approved data safety monitoring plan  
26 and are not described fully in the protocol manuscript.  
27
- 28 • 22: n/a; Plans for adverse events are detailed in the IRB-approved data safety monitoring plan  
29 and are not described fully in the protocol manuscript.  
30
- 31 • 23: n/a; Plans for trial conduct audits are detailed in the IRB-approved data safety monitoring  
32 plan and are not described fully in the protocol manuscript.  
33
- 34 • 26b: n/a; ancillary study consent not included in protocol manuscript  
35
- 36 • 27: 17; IRB approval has been obtained for all aspects of the study, including the collection and  
37 protection of participant confidentiality and personal information  
38
- 39 • 29: n/a; Data access enumerated in the IRB-approved Data Safety Monitoring Plan and protocol  
40
- 41 • 30: n/a; This trial has been designated as minimal risk by the UAB IRB.  
42
- 43 • 31b: n/a; author contributions detailed on page 27 and no professional writers used  
44
- 45 • 31c: n/a; no current plans exist for granting public access to full protocol, participant dataset, or  
46 statistical code.  
47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 33: n/a; This study collects no biological specimen. The SPIRIT Explanation and Elaboration paper is distributed under the terms of the Creative Commons Attribution License CC-BY-NC. This checklist was completed on 19. April 2023 using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

For peer review only

# BMJ Open

## Protocol for WeExPAnd: a prospective, mixed-methods pilot demonstration study to increase access to pre-exposure prophylaxis among women vulnerable to HIV infection in the US South

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-075250.R1
Article Type:	Protocol
Date Submitted by the Author:	19-May-2023
Complete List of Authors:	<p>Psaros, Christina; Massachusetts General Hospital Department of Psychiatry; Harvard Medical School Department of Psychiatry          Goodman, Georgia; Massachusetts General Hospital Department of Psychiatry; Brigham and Women's Hospital Department of Emergency Medicine          McDonald, Victoria; The University of Alabama at Birmingham School of Nursing,          Ott, Corilyn; The University of Alabama at Birmingham School of Nursing; The University of Alabama at Birmingham Heersink School of Medicine          Blyler, Abigail; University of Pennsylvania School of Arts and Sciences          Rivas, Alexa; Massachusetts General Hospital Department of Psychiatry          Shan, Liang; The University of Alabama at Birmingham School of Nursing          Campbell, Marquette; Whatley Health Services, Inc. - Maude L. Whatley Health Center          Underwood, Eric; Whatley Health Services, Inc. - Maude L. Whatley Health Center          Krakower, Douglas; The Fenway Institute at Fenway Health; Beth Israel Deaconess Medical Center          Elopre, Latesha; The University of Alabama at Birmingham Heersink School of Medicine          Kudroff, Kachina; The University of Alabama at Birmingham Heersink School of Medicine          Sherr, Kenneth H.; University of Washington Department of Global Health          Kempf, Mirjam-Colette ; The University of Alabama at Birmingham School of Nursing; The University of Alabama at Birmingham Heersink School of Medicine</p>
<b>Primary Subject Heading</b>:	HIV/AIDS
Secondary Subject Heading:	Infectious diseases, Sexual health, Communication, Epidemiology, Evidence based practice
Keywords:	HIV & AIDS < INFECTIOUS DISEASES, Feasibility Studies, Health Equity, Health Education, SEXUAL MEDICINE, Primary Prevention



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



SCHOLARONE™  
Manuscripts

**Protocol for WeExPAnd: a prospective, mixed-methods pilot demonstration study to increase access to pre-exposure prophylaxis among women vulnerable to HIV infection in the US South**

Christina Psaros<sup>1</sup>, Georgia R. Goodman<sup>1,2,3</sup>, Victoria McDonald<sup>4</sup>, Corilyn Ott<sup>4,5</sup>, Abigail Blyler<sup>6</sup>, Alexa Rivas<sup>1</sup>, Liang Shan<sup>4</sup>, Marquetta Campbell<sup>7</sup>, Eric Underwood<sup>7</sup>, Douglas Krakower<sup>3,8</sup>, Latesha Elope<sup>5</sup>, Kachina Kudroff<sup>5</sup>, Kenneth Sherr<sup>9</sup>, Mirjam-Colette Kempf<sup>4,5,10</sup>

1 Department of Psychiatry, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA

2 Department of Emergency Medicine, Brigham and Women's Hospital, Boston, MA, USA

3 The Fenway Institute, Fenway Health, Boston, MA, USA

4 School of Nursing, University of Alabama at Birmingham, Birmingham, AL, USA

5 School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA

6 Positive Psychology Center, University of Pennsylvania, Philadelphia, PA, USA

7 Whatley Health Services, Inc., Maude L. Whatley Health Center, Tuscaloosa, AL, USA

8 Beth Israel Deaconess Medical Center, Boston, MA, USA

9 Department of Global Health, University of Washington, Seattle, WA, USA

10 School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USA

**Correspondence to:**

Christina Psaros, PhD, One Bowdoin Square, 7th Floor, Boston, MA, 02114, USA

Email: [cpsaros@mgh.harvard.edu](mailto:cpsaros@mgh.harvard.edu)

**Study sponsor:** University of Alabama at Birmingham, School of Nursing, 1701 University Blvd, Birmingham, AL, 35294, USA

## Abstract

**Introduction:** African American women (AA), particularly those living in the southeastern United States (US), experience disproportionately high rates of HIV infection. Pre-exposure prophylaxis (PrEP) is a highly effective HIV prevention tool that may circumvent barriers to traditional HIV prevention tools, such as condom use; however, very little is known about how to improve PrEP access and uptake among AA women who may benefit from PrEP use. This project aims to understand how to increase PrEP access among AA women in the rural US South, which may ultimately affect HIV incidence in this population.

**Methods and analysis:** The goal of the current study is to systematically adapt a patient-provider communication tool to increase PrEP uptake among AA women receiving care at a federally qualified health center (FQHC) in Alabama. We will use an iterative implementation process, by assessing the feasibility, acceptability, and preliminary impact of the tool on PrEP uptake, using a pilot pre-/post-intervention design (N=125). We will evaluate women's reasons for declining a referral to a PrEP provider, reasons for incomplete referrals, reasons for not initiating PrEP after a successful referral, and ongoing PrEP use at 3 and 12 months after PrEP initiation among our sample. The proposed work will significantly contribute to our understanding of factors impacting PrEP uptake and use among AA women, particularly in underserved areas in the Deep South that are heavily impacted by the HIV epidemic and experience worse HIV-related health outcomes relative to other areas in the US.

**Ethics and dissemination:** This protocol has been approved by the Institutional Review Board (IRB) at University of Alabama at Birmingham (Birmingham, AL; protocol 300004276).

1  
2  
3 All participants will review a detailed informed consent form approved by the IRB and will  
4  
5 provide written or verbal informed consent prior to enrollment. Results will be disseminated  
6  
7 through peer-reviewed manuscripts, reports, and local, national, and international presentations.  
8  
9

10 **Study registration:** ClinicalTrials.gov, NCT04373551.  
11  
12  
13

### 14 **Strengths and limitations of this study**

- 16  
17 • Application of an implementation science framework facilitates rapid implementation,  
18  
19 evaluation, and modification of a novel patient-provider communication intervention to  
20  
21 increase pre-exposure prophylaxis (PrEP) awareness and potential uptake for women in a US  
22  
23 region where HIV transmission remains comparatively high.
- 24  
25 • Provides data on PrEP uptake and key social, behavioral, and cultural factors associated with  
26  
27 PrEP uptake among African American women in the US South, who remain under-  
28  
29 represented in PrEP research despite being disproportionately affected by HIV.  
30  
31
- 32  
33 • Expands knowledge base on PrEP attitudes and experiences among health care providers  
34  
35 within a Federally Qualified Health Care Center (FQHC) in the US South, where many  
36  
37 women who may benefit from PrEP enter the health care system.
- 38  
39 • Challenges and barriers identified by participants and providers throughout the adaptation  
40  
41 process may include contextual, structural, and system-level factors that are beyond the scope  
42  
43 of this communication intervention.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Introduction

The Deep South region of the United States (US) bears the greatest burden of the HIV epidemic in the US, with rural counties disproportionately affected and underserved by both HIV care and prevention services.<sup>1,2</sup> Of the more than 1.1 million people living with HIV in the US in 2018, women accounted for nearly a quarter (23%) of all cases and a significant portion (19%) of new cases, with most new cases attributed to heterosexual contact (85%).<sup>3</sup> Despite representing just 13% of the US female population, African American (AA) women accounted for 55% of new HIV diagnoses among all women in the US in 2019.<sup>2</sup> In 2016, the rate of new HIV diagnoses among AA women was 15 times higher than that of White women,<sup>3</sup> and in 2018, HIV infection ranked in the top eight leading causes of death among AA women aged 20-44 in the US.<sup>4</sup> The elevated HIV risk profile among AA women in the South may reflect factors unique to rural areas, such as the prevalence of small sexual networks resulting in cyclical HIV transmission patterns<sup>5</sup> and barriers to HIV prevention rooted in structural racism such as high incarceration rates among male AA populations, limited awareness of and access to effective contraception and sexual health interventions, higher rates of concurrent partnerships among AA men in AA women's sexual networks, and financial and transportation-related barriers to accessing HIV/STI screening, prevention, and treatment.<sup>6-11</sup>

Traditional HIV prevention efforts, like abstinence-only education approaches that are prevalent in the rural South, have been insufficient to control high rates of sexually transmitted infections (STIs) and HIV infections. Abstinence-only education does not provide women with comprehensive information critical for maintaining sexual health.<sup>12,13</sup> Moreover, interventions promoting condom use, partner-based testing, and/or monogamous relationships are dependent on behaviors of women's sexual partners and, therefore, may be outside each woman's direct

1  
2  
3 control. AA women experiencing financial challenges may be financially dependent on male  
4 partners; they may also be experiencing intimate partner violence, further complicating their  
5 ability to make independent sexual health decisions.<sup>14,15</sup> Given disproportionate diagnoses and  
6 mortality among AA women, along with limitations to non-biomedical HIV prevention  
7 methods, novel and more effective approaches to HIV prevention are necessary.  
8  
9  
10  
11  
12  
13

14 Biomedical HIV prevention tools, including pre-exposure prophylaxis (PrEP) are  
15 promising as they can potentially minimize barriers to traditional means of HIV prevention  
16 among groups who are persistently vulnerable to HIV infection. Oral PrEP has over 90%  
17 efficacy demonstrated across numerous trials, including cisgender women, but efficacy depends  
18 on consistent daily adherence as prescribed.<sup>16</sup> Long-acting injectable PrEP is also highly  
19 efficacious for cisgender women and is now available for use in the U.S.<sup>17,18</sup> Although overall  
20 oral PrEP prescriptions in the US increased substantially between 2012 and 2017, PrEP uptake  
21 among AA women has remained low. While biomedical prevention efforts have historically  
22 focused on men who have sex with men (MSM), women have not received equitable attention  
23 reflective of the epidemiology.<sup>19</sup> Indeed, 94% of PrEP users in 2017 were male, indicating a  
24 substantial unmet need among PrEP-eligible women.<sup>18</sup> In 2016, only 11% of all PrEP users  
25 with available race/ethnicity data were from AA communities.<sup>20</sup>  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

42 Regardless of geographic location, most women in the US remain unaware of PrEP, and  
43 PrEP uptake among AA women remains low, particularly in rural areas of the US where  
44 women may have less access to healthcare and more limited knowledge of PrEP than women in  
45 urban areas.<sup>21</sup> In several studies, the majority of women participating in PrEP focus groups and  
46 staff at health services organizations were unfamiliar with PrEP as an HIV prevention tool and  
47 expressed concern about a broad lack of awareness within their communities; of the 10% of  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 women who had previously heard of PrEP, none were aware of its availability and efficacy for  
4 women.<sup>22,23</sup> However, AA women expressed being generally interested in using PrEP if  
5 available,<sup>24</sup> especially if recommended by a trusted health-care provider.<sup>25</sup>  
6  
7  
8  
9

10 Suboptimal patient-provider communication has been identified as a barrier to PrEP  
11 uptake among AA women,<sup>26</sup> as has limited provider knowledge of PrEP. Historically, the most  
12 common reported barriers to prescribing PrEP include a perceived lack of clinical training and  
13 experience in PrEP delivery, greater time investment to monitor patients on PrEP, and  
14 insufficient structural support from clinic sites.<sup>27</sup> In a 2022 survey of 359 health care providers  
15 across the US, 100% of respondents were aware of PrEP, about 97% reported willingness to  
16 prescribe PrEP, and around 80% had prescribed PrEP;<sup>28</sup> however, these statistics varied by  
17 region of practice and by race, with a higher number of providers prescribing PrEP in the West  
18 and a disproportionate number of PrEP prescriptions provided to White individuals.<sup>28</sup> A recent  
19 qualitative study among providers in Alabama indicated uncertainty about offering PrEP to AA  
20 heterosexual, cis-gender adolescent or young adult females in the absence of transactional sex  
21 or a known HIV positive partner.<sup>29</sup>  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

38 Existing literature highlights numerous barriers to effective patient-provider  
39 communication about sexual health, including time constraints, embarrassment or shame  
40 surrounding these topics, patient confidentiality concerns, and both language and cultural  
41 barriers.<sup>30-33</sup> Moreover, PrEP services are less routinely implemented in settings where many  
42 patients who may benefit from PrEP use may receive care, such as Federally Qualified Health  
43 Centers (FQHCs).<sup>34</sup> In rural areas and small metropolitan areas in particular, FQHCs offering a  
44 variety of health services, ranging from primary care to family planning, have been central to  
45 the provision of primary and preventive care to underserved populations.<sup>35</sup> Almost 6 million  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 women of reproductive age received care from FQHCs in 2012.<sup>36</sup> Of the 30 million patients  
4 served by FQHCs in 2021, 65% were racial and/or ethnic minorities and 42% lived in rural  
5 areas.<sup>37</sup> FQHCs are thus an important treatment setting for research geared toward increasing  
6 PrEP access among AA women in the rural South.  
7  
8  
9  
10

### 11 ***Study aims***

12  
13  
14  
15 This paper describes the second phase of two-phased prospective, mixed-methods pilot  
16 demonstration study. The aim of the first phase was to conduct qualitative interviews exploring  
17 preferences around patient-provider communication about HIV and PrEP services to address the  
18 needs of AA women. Participants (N=41) included FQHC patients – AA women who reported  
19 current and/or recent PrEP use (N=6) or had clinical indications for PrEP use (N=15) – as well  
20 as providers (N=20).<sup>38</sup>  
21  
22  
23  
24  
25  
26  
27

28  
29 The primary aims of this second phase are: (1) to systematically adapt a patient-provider  
30 PrEP communication tool developed by the Centers for Disease Control and Prevention  
31 (CDC)<sup>39</sup> to increase PrEP uptake at an FQHC serving a small metropolitan area as well as rural  
32 Alabama, using an iterative implementation process, and (2) to assess feasibility, acceptability,  
33 and preliminary impact of the patient-provider communication tool on PrEP uptake among AA  
34 women (up to N=125) and their providers (up to N=20) using a pilot pre-/post-intervention  
35 design.  
36  
37  
38  
39  
40  
41  
42  
43

### 44 **Methods and analysis**

#### 45 ***Study design***

46  
47  
48  
49 During this second phase of the study, the qualitative data collected in the first phase has been  
50 used to adapt a patient-provider communication tool focusing on the first steps of the PrEP care  
51 cascade, notably identifying as a person who may benefit from PrEP use and being interested in  
52  
53  
54  
55  
56  
57  
58  
59



1  
2  
3 using PrEP, among AA women receiving care at an FQHC in Alabama. For interested women,  
4 referrals to PrEP services within the health center will be facilitated. The protocol will be  
5  
6 evaluated in real-time for acceptability and feasibility using both quantitative and qualitative  
7  
8 data. The protocol will be iteratively updated until satisfactory procedures have been designed  
9  
10 and simultaneously tested for preliminary impact on PrEP uptake. We anticipate conducting  
11  
12 three waves of assessments (approximately every three to five months). Each wave will consist  
13  
14 of 25-40 participants at one enrollment (clinic) site with a target total of N=125. This protocol  
15  
16 will be tested for effectiveness, including cost-effectiveness, in a larger R01 cluster randomized  
17  
18 implementation trial at primary care and reproductive health centers serving AA women  
19  
20 vulnerable to HIV infection in the Deep South.  
21  
22  
23  
24  
25

### 26 ***Population and setting***

27  
28 Participants will include both patients (up to N=125) and healthcare providers (up to N=20)  
29  
30 recruited from one FQHC in Alabama. The participating FQHC offers PrEP services, so all PrEP  
31  
32 referrals are handled internally at the clinic. Participants will attend a total of two assessment  
33  
34 visits (baseline and 3-month assessment) and an intervention visit following the baseline  
35  
36 assessment.  
37  
38  
39

### 40 ***Eligibility criteria***

41  
42 Inclusion criteria for patients include: (1) self-identified cisgender women; (2) AA race; (3) age  
43  
44 18 or older; (4) not living with HIV according to self-report (5) any sex with male partners in  
45  
46 past six months or anticipated sex in the next 6 months; (6) primary language English; and (7)  
47  
48 willing and able to give informed consent. Inclusion criteria for healthcare providers includes:  
49  
50 (1) fluency in English; (2) identifies as a physician, nurse practitioner, physician assistant, nurse,  
51  
52 medical assistant, social worker/counselor or other potential PrEP service provider; and (3)  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 willing and able to give informed consent. Potential participants may be excluded if the principal  
4  
5 investigators determine, on a case-by-case basis, that their participation would be medically  
6  
7 unsafe, complicate interpretation of study findings, or otherwise interfere with achieving study  
8  
9 objectives.

### 11 12 ***Theoretical framework***

13  
14 The Exploration, Preparation, Implementation, and Sustainment (EPIS) Implementation  
15  
16 Framework<sup>40</sup> is a meta-theoretical framework that incorporates components from multiple  
17  
18 evidence-based implementation process theories and provides a platform to guide intervention  
19  
20 planning, adaptation, and implementation (Figure 1). The EPIS guided the development and  
21  
22 evaluation of multiple implementation trials<sup>41,42</sup> and will be used as the overarching  
23  
24 methodological framework to guide intervention adaptation in this study. EPIS is segmented into  
25  
26 four stages: *Exploration* (i.e., organization, provider, and client-level factors that identify  
27  
28 potential barriers/facilitators for PrEP uptake); *Preparation* (i.e., adapting intervention to  
29  
30 enhance PrEP uptake); *Implementation* (i.e., training, coaching, and active facilitation of patient-  
31  
32 provider communication intervention); and *Sustainment* (i.e., PrEP uptake and adherence).  
33  
34  
35  
36

37  
38 Furthermore, the Dynamic Adaptation Process (DAP) framework, which is part of the  
39  
40 *Preparation* and *Implementation* phases of EPIS, will be used in the adaptation of the patient-  
41  
42 provider communication tool (Figure 1). The DAP provides direction for activities during each  
43  
44 EPIS phase and a continuously iterative, data-informed approach to support intervention  
45  
46 implementation.<sup>43</sup> Developed for the adaptation of evidence-based interventions (EBIs), it  
47  
48 provides a model framework that includes adaptations tailored to specific subgroups. The DAP  
49  
50 provides a process for pre-assessment, convening an “implementation resource team” to guide  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 the implementation process, and use of audit and feedback data to help guide appropriate EBI  
4  
5 adaptation.

### 6 7 ***Outcome variables***

8  
9  
10 Primary outcomes will include intervention feasibility, acceptability, and PrEP uptake.

11  
12 Secondary outcomes will include PrEP adherence and clinic visit adherence. Psychosocial  
13  
14 factors will also be measured to characterize the sample and assess potential mediating and  
15  
16 moderating factors associated with the outcome measures. All measures and timing of  
17  
18 assessments are provided in Table 1.

### 19 20 21 ***Feasibility***

22  
23  
24 We will measure the number of individuals screened, number of eligible individuals enrolled,  
25  
26 and number of enrolled participants who initiate PrEP and adhere to their prescribed regimen.

27  
28 We will also track reasons for declining enrollment, prematurely  
29  
30 leaving the study, declining a referral, not attending a PrEP clinic visit, and/or discontinuing  
31  
32 PrEP. Recruitment and scheduling strategies, participant contact, and feasibility of administering  
33  
34 instruments (e.g., assessment duration), will be documented.

### 35 36 37 ***Acceptability***

38  
39  
40 Acceptability will be assessed through individual in-depth qualitative interviews at the end of the  
41  
42 study. Interviews will explore participants' experiences with and perceptions of the study, and  
43  
44 their evaluations of the patient-provider communication tool to facilitate PrEP uptake. Patient  
45  
46 and provider satisfaction with the intervention will be assessed via the Client Satisfaction  
47  
48 Questionnaire (CSQ-8)<sup>44</sup> and the Behavioral Interventionist Satisfaction Survey (BISS).<sup>45</sup>

### 49 50 51 ***PrEP uptake***

**Table 1.** Measures to be administered at each assessment visit

Patients	BL	PT	3M	12M
<b>Recruitment:</b> Number screened; number of eligible individuals enrolled; reasons for declining enrollment or leaving study; participant contact throughout study; recruitment/scheduling strategies; feasibility of administering instruments/questions	X		X	
<b>PrEP referral:</b> Number of patients referred; number of patients accepting referral; reasons for declining referral; reasons for unsuccessful or incomplete referral		X	X	X
<b>PrEP uptake:</b> Ratio of patients initiating PrEP to the number eligible patients screened and referred (measured throughout)			X	X
<b>PrEP adherence:</b> Self-report via Visual Analog Scale <sup>46</sup> ; reasons for discontinuing PrEP	X		X	
<b>Clinic visit adherence:</b> Calculated as PrEP visits adhered to divided by PrEP visits scheduled			X	X
<b>Satisfaction with intervention:</b> Client Satisfaction Questionnaire (CSQ-8) <sup>44</sup>		X		
<b>Perceptions of study and evaluation of intervention:</b> Qualitative interview			X	
<b>Intimate partner violence:</b> Abuse Assessment Screen (AAS) <sup>47</sup>	X		X	
<b>Depression:</b> Center for Epidemiologic Studies Depression (CES-D) <sup>48</sup>	X		X	
<b>Spiritual support:</b> Ironson-Woods Spirituality/Religiousness (SR) <sup>49</sup>	X			
<b>Social Support:</b> Medical Outcomes Study (MOS) Social Support Survey <sup>50</sup>	X			
<b>Substance use:</b> Addiction Severity Index-Lite (ASI-Lite) <sup>51</sup>	X		X	
<b>Trauma experience:</b> Adapted from items within Project BRiGHT <sup>52</sup>	X		X	
<b>Anxiety:</b> State-Trait Anxiety Inventory State Form (STAI-S) <sup>53</sup>	X		X	
<b>Identification with organization:</b> Items drafted by study team	X			
<b>Stage of change:</b> Adapted from Stage of Change measures <sup>54,55</sup>	X	X	X	
<b>PrEP knowledge and experience:</b> Adapted from PrEP Awareness and Willingness <sup>56</sup>	X			
<b>HIV transmission knowledge:</b> Adapted from the HIV Risk Knowledge Test <sup>57</sup>	X		X	
<b>Sexual behavior:</b> Number of sexual partners; alcohol/drug use before sex; vaginal/anal sex; knowledge of partners' HIV status; condom use	X		X	
<b>Reflecting and evaluating:</b> Quantitative and qualitative feedback about progress and quality of implementation, accompanied with regular personal and team debriefing about progress and experience.				Continuous
<b>Proposed intervention modifications:</b> Both structural and didactic				Continuous
Providers	BL	PT	3M	12M
<b>Sociodemographics:</b> Age, race, ethnicity, education, clinic position	X			
<b>Implementation readiness:</b> Adapted from the Implementation Climate Scale (ICS) <sup>58</sup>	X			
<b>Dispositional innovativeness:</b> Physician-Motivation-Adoption (PMA) <sup>59</sup>	X			
<b>Culture:</b> Organizational Culture Assessment Instrument (OCAI) <sup>60</sup>	X			
<b>Patient needs and clinic resources:</b> Adapted subscales from Texas Christian University Organizational Readiness for Change Scale (TCU-ORC-D4) <sup>61</sup>	X			
<b>Stigma:</b> Adapted from the Attitude Toward People Living with HIV Scale <sup>62</sup>	X			
<b>Satisfaction with intervention:</b> Behavioral Interventionist Satisfaction Survey (BISS) <sup>45</sup> (12M only) and Short Survey (PT only)		X		X
<b>Identification with organization:</b> Qualitative interview				X
<b>Stage of change:</b> Qualitative interview				X
<b>Perceptions of study and evaluation of intervention:</b> Qualitative interview				X
<b>Reflecting and evaluating:</b> Quantitative and qualitative feedback about progress and quality of implementation, accompanied with regular personal and team debriefing about progress and experience.				X
<b>Proposed intervention modifications:</b> Both structural and didactic				Continuous

PrEP uptake will be measured by calculating the ratio of patients initiating PrEP to the number of patients eligible for the study who enrolled and were referred to PrEP services.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

---

**Note:** BL = baseline; PT = post-treatment; 3M = 3-month assessment visit; 12M = 12-month data abstraction from EMR (patients) or assessment visit (provider)

For peer review only

### *PrEP adherence*

Self-report (i.e., Visual Analog Scale) will be used to assess patients' adherence to taking PrEP as prescribed, as is currently standard practice in the participating clinics.<sup>63</sup> Reasons for discontinuing PrEP use, as applicable, will also be tracked. Participants will also be asked to rate, on a 6-point Likert scale, their ability to take all medications as prescribed.

### *Clinic visit adherence*

Attendance at clinic visits will be defined as the number of PrEP visits attended divided by the number of visits scheduled. Adherence will be assessed at 3-month follow-up and 12-months via electronic medical record abstraction.

### *Psychosocial factors*

Psychosocial factors will include assessments of intimate partner violence, depression, anxiety, post-traumatic stress disorder (PTSD), sexual behaviors, HIV transmission knowledge, substance use, social support, and spirituality/religiousness.

### ***Intervention adaptation***

#### *Adaptation activities*

Based on the formative evaluation in the first phase of this study, involving qualitative interviews with patients and providers (i.e., *Exploration* phase), a first draft of the patient-provider communication tool was produced. An adaptation plan as described by Aarons and colleagues<sup>40</sup> was used to document changes (i.e., new activities and materials to be included) to the protocol and reasons for such changes or additions. Given the minority status of our target population, it was anticipated that cultural adaptations would include process and content changes relevant to AA women vulnerable to HIV infection.<sup>64,65</sup> Adaptation was considered on the patient, provider, and organizational levels as per the EPIS.

1  
2  
3 During the *Preparation* phase, an Implementation Resource Team (IRT) was convened to  
4 review the first draft of the adapted patient-provider communication tool. The IRT was  
5  
6 comprised of experts in implementation science and PrEP delivery, representatives of the clinic  
7  
8 administration/staff (at both the FQHCs and the PrEP clinics), potential PrEP candidates and  
9  
10 PrEP users, providers, and research team members. A second draft of the adapted  
11  
12 communication tool integrated recommendations made and measures added by the IRT,  
13  
14 maintaining the core elements of the patient-provider communication tool and considering the  
15  
16 limitations and needs of the study sites.  
17  
18  
19  
20

### 21 ***Intervention implementation***

#### 22 *Provider recruitment and training*

23  
24 Provider participants will be identified by the partnering clinic's study research assistant (RA).  
25  
26 The study RA will contact study research staff on participating providers' behalf. Recruited  
27  
28 providers will complete an informed consent form and baseline assessment. Links to the  
29  
30 assessment battery will be sent to providers via email by research team members. Signed consent  
31  
32 forms and baseline assessment responses will be directly entered and stored in a secure Research  
33  
34 Electronic Data Capture (REDCap) database.  
35  
36  
37  
38  
39

40 Enrolled providers will receive training in use of the patient-provider communication tool  
41  
42 and best practices for prescribing PrEP. Training will be directed by health care practitioners  
43  
44 with extensive experience in PrEP prescribing, training providers in PrEP prescribing, and/or  
45  
46 managing PrEP-related logistics. Provider training will consist of two parts: first, providers will  
47  
48 watch two training videos, which will include an overview of PrEP basics and the study's  
49  
50 patient-provider communication tool; second, providers will participate in a live virtual training  
51  
52 session with trainers, including an interactive roleplay using parts of the patient-provider  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 communication tool, all of which has been piloted during phase I. Additional trainings and  
4  
5 preparation sessions may be held in-person at the clinic site or by phone as-needed.  
6

### 7 *Patient recruitment*

8  
9  
10 Patient participants will be recruited in three ways: (1) study RA will pre-screen potential  
11  
12 participants through their electronic medical records (EMR) and flag any patients with upcoming  
13  
14 clinic visits who meet study eligibility criteria; (2) flyers will be posted in clinic waiting areas;  
15  
16 and (3) health care providers at the participating clinic will directly refer interested patients who  
17  
18 may be eligible to participate in the study. If a patient is recruited through EMR pre-screen, they  
19  
20 will be formally screened by the study RA during their routine clinic visit. If a patient is recruited  
21  
22 via flyer or provider referral, they will either contact the study RA by phone (using the phone  
23  
24 number listed on the flyer) or may provide permission to be contacted by the study RA directly,  
25  
26 who will then screen the prospective participant by phone. All individuals who meet inclusion  
27  
28 criteria will be invited to complete the informed consent process at the baseline visit (Figure 2).  
29  
30  
31

### 32 *Informed consent*

33  
34  
35 All participants will complete a baseline assessment visit either in-person or by phone, in which  
36  
37 they will review an informed consent form, including a detailed explanation of all study  
38  
39 procedures, information about potential risks and benefits of participation, and contact  
40  
41 information for the study team in the event of further questions. The consent form will also state  
42  
43 that participation is voluntary, that they can withdraw from the study at any time, and that study  
44  
45 participation is in no way related to their health care, including receipt of PrEP services. Written  
46  
47 or verbal consent will be obtained, and a copy of the signed consent form will be provided to  
48  
49  
50  
51 participants.  
52

### 53 *Study assessments and intervention*



1  
2  
3 Enrolled patients will complete a quantitative assessment during the baseline visit, administered  
4 via REDCap,<sup>66</sup> which will include sociodemographics and measures of anxiety, depression,  
5 interpersonal violence, substance use, PrEP awareness, sexual behaviors, PTSD as well as  
6 spiritual/emotional support. Patients will then be scheduled to meet with a provider, who will use  
7 the newly adapted PrEP patient-provider communication tool. Patients who are interested in  
8 receiving a referral for PrEP after completing the intervention will be referred to the in-house  
9 PrEP clinic; this referral will include a “warm hand-off” by a provider or PrEP navigator.  
10 Providers will document the visit in patients’ electronic health records per standard clinic  
11 practice. Referrals will be made if domestic or intimate partner violence, and/or suicidal ideation  
12 are indicated in the baseline assessment.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

26 Patients and providers at the local PrEP clinic will then jointly decide whether to initiate  
27 PrEP after referral. Providers at the PrEP clinics will be responsible for all aspects of PrEP care,  
28 including reviewing lab results, reinforcing educational messages around adherence and  
29 additional HIV/STI prevention options, and conducting patient examinations as needed,  
30 consistent with their current PrEP delivery practices. Regardless of PrEP initiation, patients will  
31 be scheduled for a 3-month follow-up study visit conducted via phone. During implementation,  
32 quarterly feedback will be provided by the IRT (or more frequently if needed), who will evaluate  
33 whether further adaptations are needed to the patient-provider communication intervention. IRT  
34 members will be comprised of experts in implementation science and PrEP delivery,  
35 representatives of the clinic administration and staff at local FQHCs, potential PrEP candidates  
36 and users, providers, and members of the investigative team. Best practices for intervention  
37 delivery process, type, and frequency of communication with AA women vulnerable to HIV  
38 infection will also be assessed.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### *Remuneration*

Patients will be remunerated a total of \$100 for their participation and transportation costs, independent of PrEP uptake. Providers will receive \$50 for their time and 1.5 credit hours of continuing education credit for their participation in the study training.

### *Patient and public involvement*

Patient and PrEP healthcare provider involvement is incorporated into the design and conduct of this implementation science study. The Implementation Resource Team described above is comprised of FQHC patients and PrEP navigators/providers as well as research team members. The IRT guides and informs the intervention design and implementation of the study throughout, including the interpretation and dissemination of results.

### *Data analyses*

The feasibility, acceptability, and preliminary impact of this intervention will be assessed among patients and providers using this pre-/post-intervention design. Quantitative data will be analyzed using SPSS or R. Feasibility will be determined by evaluation of recruitment and retention, number of PrEP referrals, PrEP initiation, PrEP adherence, and clinic visit adherence. Acceptability will be measured using in-depth, individual, qualitative exit interviews and satisfaction surveys. Continuous feedback from participants and experts relevant to the population and outcomes studied will assure feasibility, acceptability, and appropriateness of the adapted intervention. Structural and content related changes of the intervention will be based on the feedback provided by patients and providers.

Primary and secondary outcomes will be assessed by characterizing the sample using descriptive statistics, computing confidence intervals on these measures, and exploring patient and implementation characteristics as possible moderators of these outcomes in order to inform

1  
2  
3 the design of our future trial. Measures of effect size (e.g., Cohen's d, Cohen's r, Cramer's V,  $R^2$ ,  
4 etc.) will be used to determine the characteristics that individually appeared to be relevantly  
5 associated with PrEP uptake and secondary outcomes in the sample.  
6  
7

8  
9  
10 To examine impact of the protocol adaptation, we will use calendar quarter of entry in the  
11 study as a possible moderator. Multivariable exploratory analyses will be conducted using non-  
12 parametric methods<sup>67</sup> including penalized regression (LASSO) and Random Forest, to determine  
13 if the sample data suggest a smaller set of relevant characteristics based on their cross-validated  
14 predictive ability of each outcome. These data will be useful in tailoring our implementation  
15 approach based on empirical observation. On *a priori* conceptual considerations, we expect age,  
16 intimate partner violence and sexual risk behavior to be supported by the data as moderators of  
17 PrEP uptake. In addition, exploratory mediation analyses will be conducted based on conceptual  
18 considerations using the procedures outlined by Hayes.<sup>68</sup>  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

30  
31 Clinics' electronic medical record data be used to estimate PrEP uptake, based on the  
32 number of PrEP-eligible AA women who have been referred to PrEP in the three years pre- and  
33 post-implementation of the protocol (i.e., pre-/post-test design). Binomial logistic models  
34 (events/trials syntax) will be fitted with time-period and clinic as main effects to estimate the  
35 differences in uptake proportions between pre- and post-protocol time periods. To determine the  
36 specific impact of the iterative process of protocol adaptation during the year of implementation,  
37 we will fit a logistic model for uptake with bi-monthly assessment wave number (three waves) as  
38 a categorical predictor. *A priori*, we expect a positive relationship between the assessment wave  
39 number and the odds of uptake, indicating that as the protocol became more refined during the  
40 year, PrEP uptake increased.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

### 53 ***Sample size***

54  
55  
56  
57  
58  
59  
60

1  
2  
3 To examine differences in PrEP uptake rates in the participating clinic comparing three years  
4 before and the year after the implementation of the protocol, we estimate that there are at least  
5  
6 3,500 AA PrEP-eligible women serviced annually. Assuming an uptake proportion of 0.0125  
7  
8 ( $44/3500 = 1.25\%$ ) estimated retrospectively in the three years prior to study implementation and  
9  
10 a within-subject correlation of 0.65, at a significance level of 0.01, a sample size of 3,500  
11  
12 provides 90% power to detect an increase in proportion of uptake of .007 ( $.7\%=25/3500$ );  
13  
14 however, though power is high, interpretation of this inference would be restricted to the  
15  
16 particular clinic in the study or clinics with similar characteristics.  
17  
18  
19  
20

21 The target sample size of  $N=125$  is informative to provide reasonable range estimates (in  
22 the form of 95% confidence intervals) for the measures of interest in this study. For instance,  
23 assuming that 25% ( $n=31/125$ ) of the in-study clients referred to PrEP in fact initiate PrEP, the  
24 width of the confidence interval for this percentage is 15.8%, and assuming that age has a  
25 standard deviation of 5 years and age moderates PrEP uptake, the confidence interval width for  
26 the mean difference in age between those who initiate PrEP ( $n=31$ ) and those who do not ( $n=94$ )  
27 is 4.1 years (computations conducted using PASS 23 software). Given that this is an exploratory  
28 study with several primary and secondary outcomes, we do not have an expected effect size, but  
29 our study is nonetheless powered to detect a moderate effect.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

### 42 **Ethics and dissemination**

43  
44 The study will be conducted under a single IRB (sIRB) at the University of Alabama at  
45 Birmingham (UAB), with reliant sites at Massachusetts General Hospital and Beth Israel  
46 Deaconess Medical Center. Ethics approval was obtained for all aspects of this study by the IRB  
47 at UAB (UAB; protocol 300004276), where the work is being conducted. All participants will  
48 receive detailed written information on the purpose and procedures of the study and will provide  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 2.** WeExPAnd trial registration data

Data category	Information
Primary registry and trial identifying number	ClinicalTrials.gov NCT04373551
Date of registry in primary registry	May 4, 2020
Secondary identifying numbers	300003885, 1R34MH118044-01A1
Source(s) of monetary or material support	National Institute of Mental Health
Primary sponsor	National Institute of Mental Health
Secondary sponsor	N/a
Contact for public queries	Mirjam-Colette Kempf, PhD [mkempf@uab.edu]
Contact for scientific queries	Mirjam-Colette Kempf, PhD University of Alabama at Birmingham
Public title	PrEP Demonstration Project Among Women at Risk for HIV Infection
Scientific title	N/a
Countries of recruitment	United States
Health condition(s) or problem(s) studied	HIV-infection/AIDS

written or verbal informed consent prior to enrollment. Study updates, preliminary findings, and final results will be disseminated through publication of manuscripts in peer-reviewed journals, as well as through reports to the National Institutes of Health, and through local, national, and international presentations at HIV-focused conferences and meetings. The study is registered at ClinicalTrials.gov, NCT04373551 (Table 2).

### *Study status*

At the time of writing, a total of 49 patients and nine providers have been enrolled in the study; screening and enrollment is ongoing. The PIs determined that a single FQHC site, rather than the two FQHCs initially identified, would both provide sufficient data to pilot test the patient-provider communication tool and allow for better concentration of implementation resources; as such, only one site has been activated with a target enrollment of N=125. The study will be completed by June 2024.

<b>Intervention(s)</b>	Behavioral: Cultural adaptation of a patient-provider communication tool
<b>Key inclusion and exclusion criteria</b>	Ages eligible for study: $\geq 18$ years Sexes eligible for study: cisgender female Gender-based eligibility: yes Accepts health volunteers: no
	Patients Inclusion criteria: African American cisgender women aged 18 years or older without HIV; report HIV risk and/or recent PrEP use; English-speaking
	Providers Inclusion criteria: Physicians, nurse practitioners, physician assistants, nurses, medical assistants, social workers/counselors or other potential/actual PrEP service providers; English-speaking
<b>Study type</b>	Interventional (Clinical Trial)
	Allocation: N/a
	Primary purpose: Health Services Research
	Phase: N/a
<b>Study start date</b>	April 14, 2020
<b>Target sample size</b>	125 participants
<b>Recruitment status</b>	Enrolling by invitation
<b>Primary outcome(s)</b>	PrEP uptake changes [Time Frame: baseline, 3 months, and 12 months] Intervention feasibility changes [Time Frame: baseline, 3 months, and 12 months] Intervention acceptability [Time Frame: Through study completion, an average of 12 months]
<b>Secondary outcome(s)</b>	PrEP adherence [Time Frame: 3 months and 12 months] Clinic visit adherence changes [Time Frame: 3 months and 12 months] Biological measures of HIV, STIs and pregnancy [Time Frame: baseline, 3 months, and 12 months]

\*\*\* \*\*

**Contributors:** C.P. and M.C.K. conceived and designed the pilot demonstration study and its protocol and directed protocol activities. G.R.G. drafted the protocol manuscript and designed several manuscript tables. V.M., C.O., A.B., and A.R. contributed to drafting, editing, and finalizing the protocol manuscript and the design of the overall project protocol. L.S. planned and edited the statistical methods section of the manuscript. M.C. and E.U. advised on the protocol methods and provided comments on manuscript. D.K., L.E., K.K., and K.S. advised on

1  
2  
3 the structure and implementation of the protocol and provided comments on the protocol  
4  
5 manuscript.  
6

7  
8 **Funding:** This work is supported by the National Institute of Mental Health (NIMH; grant  
9  
10 number 5R34MH118044-03).  
11

12 **Competing interests:** None declared.  
13

14 **Protocol issue date:** 07 Mar 2022  
15

16 **Protocol version number:** 01  
17  
18

## 19 20 21 22 **References** 23

- 24 1. Centers for Disease Control and Prevention. HIV in the Southern United States Issue Brief.  
25  
26 Centers for Disease Control and Prevention. Updated September 2019. Accessed September  
27  
28 2022. <https://www.cdc.gov/hiv/pdf/policies/cdc-hiv-in-the-south-issue-brief.pdf>  
29  
30
- 31 2. Centers for Disease Control and Prevention. Diagnoses of HIV Infection in the United States  
32  
33 and Dependent Areas 2019: Special Focus Profiles. Centers for Disease Control and  
34  
35 Prevention. Updated October 15, 2021. Accessed September 2022  
36  
37 [https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-32/content/special-focus-](https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-32/content/special-focus-profiles.html#Women)  
38  
39 [profiles.html#Women](https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-32/content/special-focus-profiles.html#Women)  
40  
41
- 42 3. Kaiser Family Foundation. Women and HIV in the United States. KFF. Updated March 9,  
43  
44 2020. Accessed September 2022. [https://www.kff.org/hivaids/fact-sheet/women-and-hivaids-](https://www.kff.org/hivaids/fact-sheet/women-and-hivaids-in-the-united-states/)  
45  
46 [in-the-united-states/](https://www.kff.org/hivaids/fact-sheet/women-and-hivaids-in-the-united-states/)  
47  
48
- 49 4. Centers for Disease Control and Prevention. Leading Causes of Death – Females – Non-  
50  
51 Hispanic Black – United States, 2018. Centers for Disease Control and Prevention. Updated  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 March 3, 2022. Accessed September 2022.

4  
5 <https://www.cdc.gov/women/lcod/2018/nonhispanic-black/index.htm>

- 6  
7  
8 5. Adimora AA, Schoenbach VJ, Doherty IA. HIV and African Americans in the southern  
9  
10 United States: sexual networks and social context. *Sex Transm Dis*. 2006;33(7 Suppl):S39-  
11  
12 45. doi: 10.1097/01.olq.0000228298.07826.68  
13  
14  
15 6. Bowleg L, Malekzadeh AN, Mbaba M, et al. Ending the HIV Epidemic for All, Not Just  
16  
17 Some: Structural Racism as a Fundamental but Overlooked Social-Structural Determinant of  
18  
19 the U.S. HIV Epidemic. *Curr Opin HIV AIDS*. 2022;17(2):40–5. doi:  
20  
21 10.1097/COH.0000000000000724  
22  
23  
24 7. Adimora AA, Schoenbach VJ, Martinson FE, et al. Heterosexually transmitted HIV infection  
25  
26 among African Americans in North Carolina. *J Acquir Immune Defic Syndr*. 2006;41:616–  
27  
28 23. doi: 10.1097/01.qai.0000191382.62070.a5  
29  
30  
31 8. Adimora AA, Schoenbach VJ, Doherty IA. Concurrent sexual partnerships among men in the  
32  
33 United States. *Am J Public Health*. 2007;97(12):2230–7. doi: 10.2105/AJPH.2006.099069  
34  
35  
36 9. Doherty IA, Schoenbach VJ, Adimora AA. Sexual mixing patterns and heterosexual HIV  
37  
38 transmission among African Americans in the southeastern United States. *J Acquir Immune*  
39  
40 *Defic Syndr*. 2009;52(1):114–20. doi: 10.1097/QAI.0b013e3181ab5e10  
41  
42  
43 10. Harawa N AA. Incarceration, African Americans, and HIV: Advancing a research agenda. *J*  
44  
45 *Natl Med Assoc*. 2008;100(1):57-62. doi: 10.1016/s0027-9684(15)31175-5  
46  
47  
48 11. Aaron E, Blum C, Seidman D, Hoyt MJ, Simone J, Sullivan M, et al. Optimizing Delivery of  
49  
50 HIV Preexposure Prophylaxis for Women in the United States. *AIDS Patient Care STDS*.  
51  
52 2018;32(1):16-23. doi: 10.1089/apc.2017.0201  
53  
54  
55  
56  
57  
58  
59  
60



- 1  
2  
3 12. Stanger-Hall KF, Hall DW. Abstinence-Only Education and Teen Pregnancy Rates: Why We  
4  
5 Need Comprehensive Sex Education in the U.S. *PLoS One*. 2011;6(10):e24658. doi:  
6  
7 10.1371/journal.pone.0024658  
8  
9
- 10 13. Jozkowski KN, Crawford BL. The Status of Reproductive and Sexual Health in Southern  
11  
12 USA: Policy Recommendations for Improving Health Outcomes. *Sex Res Soc Policy*.  
13  
14 2015;13:252–62. doi: <https://doi.org/10.1007/s13178-015-0208-7>  
15  
16
- 17 14. Cavanaugh CE, Hansen NB, Sullivan TP. HIV Sexual Risk Behavior Among Low-Income  
18  
19 Women Experiencing Intimate Partner Violence: The Role of Posttraumatic Stress Disorder.  
20  
21 *AIDS Behav*. 2010;14(2):318–27. doi: 10.1007/s10461-009-9623-1  
22  
23
- 24 15. Frew PM, Parker K, Vo L, et al. Socioecological factors influencing women’s HIV risk in the  
25  
26 United States: qualitative findings from the women’s HIV SeroIncidence study (HPTN 064).  
27  
28 *BMC Public Health*. 2016;16:803. doi: <https://doi.org/10.1186/s12889-016-3364-7>  
29  
30
- 31 16. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in  
32  
33 heterosexual men and women. *N Engl J Med*. 2012;367(5):399-410. doi:  
34  
35 10.1056/NEJMoa1108524  
36  
37
- 38 17. World Health Organization. Trial results reveal that long-acting injectable cabotegravir as  
39  
40 PrEP is highly effective in preventing HIV acquisition in women. World Health  
41  
42 Organization. Updated November 9, 2020. Accessed September 2022.  
43  
44 [https://www.who.int/news/item/09-11-2020-trial-results-reveal-that-long-acting-injectable-](https://www.who.int/news/item/09-11-2020-trial-results-reveal-that-long-acting-injectable-cabotegravir-as-prep-is-highly-effective-in-preventing-hiv-acquisition-in-women)  
45  
46 [cabotegravir-as-prep-is-highly-effective-in-preventing-hiv-acquisition-in-women](https://www.who.int/news/item/09-11-2020-trial-results-reveal-that-long-acting-injectable-cabotegravir-as-prep-is-highly-effective-in-preventing-hiv-acquisition-in-women)  
47  
48
- 49 18. Delany-Moretlwe S, Hughes JP, Bock P, et al. Cabotegravir for the prevention of HIV-1 in  
50  
51 women: results from HPTN 084, a phase 3, randomised clinical trial. *Lancet*.  
52  
53 2022;399(10337):1779-89. doi: 10.1016/S0140-6736(22)00538-4  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 19. HIV.gov. Impact on Racial and Ethnic Minorities. HIV.gov. Updated January 20, 2023.  
4  
5 Accessed February 2023. [https://www.hiv.gov/hiv-basics/overview/data-and-trends/impact-](https://www.hiv.gov/hiv-basics/overview/data-and-trends/impact-on-racial-and-ethnic-minorities/)  
6  
7 [on-racial-and-ethnic-minorities/](https://www.hiv.gov/hiv-basics/overview/data-and-trends/impact-on-racial-and-ethnic-minorities/)  
8  
9
- 10 20. Huang YA, Zhu W, Smith DK, et al. HIV Preexposure Prophylaxis, by Race and Ethnicity  
11  
12 — United States, 2014–2016. *MMWR Morb Mortal Wkly Rep*. 2018;67:1147–50.  
13  
14 doi: <http://dx.doi.org/10.15585/mmwr.mm6741a3>  
15  
16
- 17 21. Sullivan PS, Mena L, Elore L, et al. Implementation Strategies to Increase PrEP Uptake in  
18  
19 the South. *Curr HIV/AIDS Rep*. 2019 6(4):259-69. doi: 10.1007/s11904-019-00447-4  
20  
21
- 22 22. Auerbach JD, Kinsky S, Brown G, et al. Knowledge, attitudes, and likelihood of pre-  
23  
24 exposure prophylaxis (PrEP) use among US women at risk of acquiring HIV. *AIDS Patient*  
25  
26 *Care STDS*. 2015;29(2):102-10. doi: 10.1089/apc.2014.0142  
27  
28
- 29 23. Collier KL, Colarossi LG, Sanders K. Raising Awareness of Pre-Exposure Prophylaxis  
30  
31 (PrEP) among Women in New York City: Community and Provider Perspectives. *J Health*  
32  
33 *Commun*. 2017;22(3):183-9. doi: 10.1080/10810730.2016.1261969  
34  
35
- 36 24. Sales JM, Steiner RJ, Brown JL, et al. PrEP Eligibility and Interest Among Clinic- and  
37  
38 Community-Recruited Young Black Women in Atlanta, Georgia, USA. *Curr HIV Res*.  
39  
40 2018;16(3):250-5. doi: 10.2174/1570162X16666180731143756  
41  
42
- 43 25. Wingood GM, Dunkle K, Camp C, et al. Racial Differences and Correlates of Potential  
44  
45 Adoption of Pre-exposure Prophylaxis (PrEP): Results of a National Survey. *J Acquir*  
46  
47 *Immune Defic Syndr*. 2014;63(0 1):S95–S101. doi: 10.1097/QAI.0b013e3182920126  
48  
49
- 50 26. Goparaju L, Praschan NC, Warren-Jeanpiere L, Experton LS, Young MA, Kassaye S.  
51  
52 Stigma, Partners, Providers and Costs: Potential Barriers to PrEP Uptake among US Women.  
53  
54 *J AIDS Clin Res*. 2017;8(9):730.  
55  
56  
57  
58  
59  
60

- 1  
2  
3 27. Castel AD, Feaster DJ, Tang W, et al. Understanding HIV Care Provider Attitudes Regarding  
4 Intentions to Prescribe PrEP. *J Acquir Immune Defic Syndr*. 2016;70(5):520–8. doi:  
5  
6 10.4172/2155-6113.1000730  
7  
8  
9  
10 28. Rao S, Reed AE, Parchem B, et al. Optimizing Provider Preexposure Prophylaxis (PrEP)  
11 Training: A Cross-Sectional Analysis of Recommendations from Providers Across the PrEP  
12 Implementation Cascade. *AIDS Behav*. 2022;26:218–31. doi: 10.1007/s10461-021-03375-w  
13  
14  
15  
16  
17 29. Pratt MC, Hill SV, Elope L, et al. PrEP Prescription for Black Adolescent Girls and Young  
18 Women in Alabama: Findings from a Survey of Healthcare Providers. *J Int Assoc Provid*  
19  
20  
21  
22  
23  
24 30. Hoopes AJ, Benson SK, Howard HB, et al. Adolescent Perspectives on Patient-Provider  
25 Sexual Health Communication: A Qualitative Study. *J Prim Care Community Health*.  
26  
27  
28  
29  
30  
31 31. Malta M, Todd CS, Stibich MA, et al. Patient-provider communication and reproductive  
32 health among HIV-positive women in Rio de Janeiro, Brazil. *Patient Educ Couns*.  
33  
34  
35  
36  
37  
38 32. Calabrese SK, Mayer KH. Stigma impedes HIV prevention by stifling patient-provider  
39 communication about U = U. *J Int AIDS Soc*. 2020;23(7):e25559. doi: 10.1002/jia2.25559  
40  
41  
42  
43 33. Flynn KE, Whicker D, Lin L, et al. Sexual Orientation and Patient-Provider Communication  
44 About Sexual Problems or Concerns Among US Adults. *J Gen Intern Med*.  
45  
46  
47  
48  
49 34. Tookes H, Yao K, Chueng T, et al. Pre-exposure prophylaxis access in federally qualified  
50 health centers across 11 United States metropolitan statistical areas. *Int J STD AIDS*.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 35. National Association of Community Health Centers. Health Centers' Workforce: The  
4 Backbone of Our Country's Healthcare. National Association of Community Health Centers,  
5 Inc. Updated March 2022. Accessed September 2022. [https://www.nachc.org/wp-](https://www.nachc.org/wp-content/uploads/2022/02/P-I-Brief-2022.pdf)  
6 content/uploads/2022/02/P-I-Brief-2022.pdf  
7  
8  
9  
10  
11  
12 36. Wood S, Beeson T, Bruen B, et al. Scope of family planning services available in Federally  
13 Qualified Health Centers. *Contraception*. 2014;89(2):85-90. doi:  
14 10.1016/j.contraception.2013.09.015  
15  
16  
17  
18  
19 37. National Association of Community Health Centers. America's Health Centers. National  
20 Association of Community Health Centers, Inc. Updated August 2022. Accessed September  
21 2022. [https://www.nachc.org/wp-content/uploads/2022/08/Americas-Health-Centers-](https://www.nachc.org/wp-content/uploads/2022/08/Americas-Health-Centers-2022_final.pdf)  
22 2022\_final.pdf  
23  
24  
25  
26  
27  
28 38. Psaros C, Goodman G, Blyler A, et al. Barriers to expanding PrEP uptake among cisgender  
29 African American women in the South. Abstract presented at: 11th International AIDS  
30 Society (IAS) Conference on HIV Science; July 18-21, 2021; Virtual and Berlin, Germany.  
31 Accessed September 2022. [https://www.natap.org/2021/IAS/IAS\\_59.htm](https://www.natap.org/2021/IAS/IAS_59.htm)  
32  
33  
34  
35  
36  
37 39. Centers for Disease Control and Prevention. A Guide for the Healthcare Professional:  
38 Discussing Sexual Health with Your Patients. Centers for Disease Control and Prevention.  
39 Updated 2022. Accessed September 2022.  
40 <https://www.cdc.gov/hiv/pdf/clinicians/screening/cdc-hiv-php-discussing-sexual-health.pdf>.  
41  
42  
43  
44  
45  
46 40. Aarons GA, Hurlburt M, Horwitz SM. Advancing a conceptual model of evidence-based  
47 practice implementation in public service sectors. *Adm Policy Ment Health*. 2011;38(1):4-23.  
48 doi: 10.1007/s10488-010-0327-7  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 41. Willging CE, Green AE, Ramos MM. Implementing school nursing strategies to reduce  
4  
5 LGBTQ adolescent suicide: a randomized cluster trial study protocol. *Implementation Sci.*  
6  
7 2016;11(145). doi: <https://doi.org/10.1186/s13012-016-0507-2>  
8  
9
- 10 42. Becan JE, Bartkowski JP, Knight DK, et al. A model for rigorously applying the Exploration,  
11  
12 Preparation, Implementation, Sustainment (EPIS) framework in the design and measurement  
13  
14 of a large scale collaborative multi-site study. *Health Justice.* 2018;6(1):9. doi:  
15  
16 10.1186/s40352-018-0068-3  
17  
18
- 19 43. Aarons GA, Green AE, Palinkas LA, et al. Dynamic adaptation process to implement an  
20  
21 evidence-based child maltreatment intervention. *Implementation Sci.* 2012;7(32). doi:  
22  
23 <https://doi.org/10.1186/1748-5908-7-32>  
24  
25
- 26 44. Larsen DL, Attkisson CC, Hargreaves WA, et al. Assessment of client/patient satisfaction:  
27  
28 development of a general scale. *Eval Program Plann.* 1979;2(3):197-207. doi: 10.1016/0149-  
29  
30 7189(79)90094-6  
31  
32
- 33 45. McLean KA. *Healthcare Provider Acceptability of a Behavioral Intervention to Promote*  
34  
35 *Adherence.* Master's thesis. University of Miami; 2013.  
36  
37 [https://scholarship.miami.edu/esploro/outputs/graduate/Healthcare-Provider-Acceptability-](https://scholarship.miami.edu/esploro/outputs/graduate/Healthcare-Provider-Acceptability-of-a-Behavioral/991031447949202976)  
38  
39 [of-a-Behavioral/991031447949202976](https://scholarship.miami.edu/esploro/outputs/graduate/Healthcare-Provider-Acceptability-of-a-Behavioral/991031447949202976)  
40  
41
- 42 46. Lu M, Safren SA, Skolnik PR, et al. Optimal recall period and response task for self-reported  
43  
44 HIV medication adherence. *AIDS Behav.* 2007;12(1):86-94. doi: 10.1007/s10461-007-9261-4  
45  
46
- 47 47. Laughon K, Renker P, Glass N, Parker B. Revision of the Abuse Assessment Screen to  
48  
49 Address Nonlethal Strangulation. *JOGNN.* 2008;37(4):502-7. doi:  
50  
51 <https://doi.org/10.1111/j.1552-6909.2008.00268.x>  
52  
53  
54  
55  
56  
57  
58  
59

- 1  
2  
3 48. Radloff LS. The CES-D Scale: A Self-Report Depression Scale for Research in the General  
4  
5 Population. *Applied Psychological Measurement*. 1977;1(3):385–401. doi:  
6  
7 <https://doi.org/10.1177/014662167700100306>  
8  
9
- 10 49. Ironson G, Solomon GF, Balbin EG, et al. The Ironson-woods Spirituality/Religiousness  
11  
12 Index is associated with long survival, health behaviors, less distress, and low cortisol in  
13  
14 people with HIV/AIDS. *Ann Behav Med*. 2002;24(1):34-48. doi:  
15  
16 [10.1207/S15324796ABM2401\\_05](https://doi.org/10.1207/S15324796ABM2401_05)  
17  
18
- 19 50. Sherbourne CD, Stewart AL. The MOS social support survey. *Soc Sci Med*. 1991;32(6):705-  
20  
21 14. doi: [10.1016/0277-9536\(91\)90150-b](https://doi.org/10.1016/0277-9536(91)90150-b)  
22  
23
- 24 51. McLellan AT, Luborsky L, Woody GE, et al. An improved diagnostic evaluation instrument  
25  
26 for substance abuse patients. The Addiction Severity Index. *J Nerv Ment Dis*.  
27  
28 1980;168(1):26-33. doi: [10.1097/00005053-198001000-00006](https://doi.org/10.1097/00005053-198001000-00006)  
29  
30
- 31 52. Psaros C. *The BRIgHT Program: Building Resilience in HIV Together*. Clinicaltrials.gov;  
32  
33 2018. Accessed September 2022. <https://clinicaltrials.gov/ct2/show/NCT03673098>  
34  
35
- 36 53. Skapinakis P. Spielberger State-Trait Anxiety Inventory. In: Michalos AC (eds)  
37  
38 *Encyclopedia of Quality of Life and Well-Being Research*. Springer; 2014. doi:  
39  
40 [https://doi.org/10.1007/978-94-007-0753-5\\_2825](https://doi.org/10.1007/978-94-007-0753-5_2825)  
41  
42
- 43 54. Napper LE, Branson CM, Fisher DG, et al. Assessing the validity of a single-item HIV risk  
44  
45 stage-of-change measure. *J Drug Educ*. 2008;38(1):27-37. doi: [10.2190/DE.38.1.c](https://doi.org/10.2190/DE.38.1.c)  
46  
47
- 48 55. Basta TB, Reece M, Wilson MG. Predictors of exercise stage of change among individuals  
49  
50 living with HIV/AIDS. *Med Sci Sports Exerc*. 2008;40(9):1700-6. doi:  
51  
52 [10.1249/MSS.0b013e318173f09e](https://doi.org/10.1249/MSS.0b013e318173f09e)  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 56. Taggart T, Liang Y, Pina P, Albritton T. Awareness of and willingness to use PrEP among  
4  
5 Black and Latinx adolescents residing in higher prevalence areas in the United States. *PLoS*  
6  
7 *ONE*. 2020;15(7):e0234821. doi: [https://doi.org/10.1371/ journal.pone.0234821](https://doi.org/10.1371/journal.pone.0234821)  
8  
9
- 10 57. Sikkema KJ, Heckman TG, Kelly JA, et al. HIV risk behaviors among women living in low-  
11  
12 income, inner-city housing developments. *Am J Public Health*. 1996;86(1123–1128). doi:  
13  
14 10.2105/ajph.86.8\_pt\_1.1123  
15  
16
- 17 58. Ehrhart MG, Aarons GA, Farahnak LR. Assessing the organizational context for EBP  
18  
19 implementation: the development and validity testing of the Implementation Climate Scale  
20  
21 (ICS). *Implementation Sci*. 2014;9(157). doi: <https://doi.org/10.1186/s13012-014-0157-1>  
22  
23
- 24 59. Hatz MHM, Sonnenschein T, Blankart CR. The PMA Scale: A Measure of Physicians'  
25  
26 Motivation to Adopt Medical Devices. *Value Health*. 2017;20(4):533-41. doi:  
27  
28 10.1016/j.jval.2016.12.002  
29  
30
- 31 60. Heritage B, Pollock C, Roberts L. Validation of the Organizational Culture Assessment  
32  
33 Instrument. *PLoS ONE*. 2014;9(3):e92879. doi: 10.1371/journal.pone.0092879  
34  
35
- 36 61. Institute of Behavioral Research. TCU Organizational Readiness for Change (ORC-  
37  
38 D4). Texas Christian University, Institute of Behavioral Research; 2009. Accessed September  
39  
40 2021. [https://ibr.tcu.edu/forms/organizational-staff-](https://ibr.tcu.edu/forms/organizational-staff-assessments/#:~:text=TCU%20Organizational%20Readiness%20for%20Change,individually%2C%20depending%20on%20assessment%20strategy.)  
41  
42 [assessments/#:~:text=TCU%20Organizational%20Readiness%20for%20Change,individually](https://ibr.tcu.edu/forms/organizational-staff-assessments/#:~:text=TCU%20Organizational%20Readiness%20for%20Change,individually%2C%20depending%20on%20assessment%20strategy.)  
43  
44 [%2C%20depending%20on%20assessment%20strategy.](https://ibr.tcu.edu/forms/organizational-staff-assessments/#:~:text=TCU%20Organizational%20Readiness%20for%20Change,individually%2C%20depending%20on%20assessment%20strategy.)  
45  
46
- 47 62. Stringer KL, Turan B, McCormick L, et al. HIV-Related Stigma Among Healthcare  
48  
49 Providers in the Deep South. *AIDS Behav*. 2016;20(1):115-25. doi: 10.1007/s10461-015-  
50  
51 1256-y  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 63. Montgomery MC, Oldenburg CE, Nunn AS, et al. Adherence to Pre-Exposure Prophylaxis  
4 for HIV Prevention in a Clinical Setting. *PLoS One*. 2016;11(6):e0157742. doi:  
5  
6 10.1371/journal.pone.0157742  
7  
8  
9  
10 64. Marsiglia FF, Booth JM. Cultural Adaptation of Interventions in Real Practice Settings. *Res*  
11  
12 *Soc Work Pract*. 2015;25(4):423–32. doi: 10.1177/1049731514535989  
13  
14  
15 65. Norton WE, Amico KR, Cornman DH, et al. An agenda for advancing the science of  
16  
17 implementation of evidence-based HIV prevention interventions. *AIDS Behav*.  
18  
19 2009;13(3):424-9. doi: 10.1007/s10461-009-9556-8  
20  
21  
22 66. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)--a  
23  
24 metadata-driven methodology and workflow process for providing translational research  
25  
26 informatics support. *J Biomed Inform*. 2009;42(2):377-81. doi: 10.1016/j.jbi.2008.08.010  
27  
28  
29 67. Efron B, Hastie T. *Computer Age Statistical Inference: Algorithms, Evidence, and Data*  
30  
31 *Science*. Cambridge University Press; 2016.  
32  
33  
34 68. Hayes A. *Introduction to Mediation, Moderation, and Conditional Process Analysis*. The  
35  
36 Guilford Press; 2013.  
37  
38  
39

## 40 **FIGURE TITLES AND LEGENDS**

41  
42 **Figure 1.** Overview of the Exploration, Preparation, Implementation, and Sustainment (EPIS)  
43  
44 Implementation Framework for the study

45  
46 The EPIS Implementation Framework a meta-theoretical framework incorporating components  
47  
48 from multiple implementation process theories to guide intervention planning, adaptation and  
49  
50 implementation. EPIS provides the overarching methodological framework to guide intervention  
51  
52 adaptation in this study.  
53  
54  
55  
56  
57  
58  
59  
60




1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


**Figure 2.** Flowchart of the informed consent, assessment, and intervention process for the study

For peer review only

**Figure 1: Measurement framework of EPIS stages**



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



# Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D. SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials. *BMJ*. 2013;346:e7586

	Reporting Item	Page Number
<b>Administrative information</b>		
Title	<a href="#">#1</a> Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	<a href="#">#2a</a> Trial identifier and registry name. If not yet registered, name of intended registry	28
Trial registration: data set	<a href="#">#2b</a> All items from the World Health Organization Trial Registration Data Set	28
Protocol version	<a href="#">#3</a> Date and version identifier	27
Funding	<a href="#">#4</a> Sources and types of financial, material, and other support	27
Roles and responsibilities: contributorship	<a href="#">#5a</a> Names, affiliations, and roles of protocol contributors	1 & 27

1	Roles and	<a href="#">#5b</a>	Name and contact information for the trial	1
2	responsibilities:		sponsor	
3	sponsor contact			
4	information			
5				
6				
7				
8	Roles and	<a href="#">#5c</a>	Role of study sponsor and funders, if	n/a; This funding source and
9	responsibilities:		any, in study design; collection,	sponsor had no role in the
10	sponsor and funder		management, analysis, and interpretation	design of this study and will
11			of data; writing of the report; and the	not have any role during its
12			decision to submit the report for	execution, analyses,
13			publication, including whether they will	interpretation of the data, or
14			have ultimate authority over any of these	decision to submit results.
15			activities	
16				
17				
18				
19				
20				
21	Roles and	<a href="#">#5d</a>	Composition, roles, and responsibilities	n/a; IRB has designated the
22	responsibilities:		of the coordinating centre, steering	study minimal risk; all
23	committees		committee, endpoint adjudication	aspects of the trial are
24			committee, data management team, and	overseen by the co-PIs and
25			other individuals or groups overseeing	research team
26			the trial, if applicable (see Item 21a for	
27			data monitoring committee)	
28				
29				
30				
31				
32	<b>Introduction</b>			
33				
34	Background and	<a href="#">#6a</a>	Description of research question and	3
35	rationale		justification for undertaking the trial,	
36			including summary of relevant studies	
37			(published and unpublished) examining	
38			benefits and harms for each intervention	
39				
40				
41				
42	Background and	<a href="#">#6b</a>	Explanation for choice of comparators	n/a; Single Group
43	rationale: choice of			Assignment
44	comparators			
45				
46				
47	Objectives	<a href="#">#7</a>	Specific objectives or hypotheses	6
48				
49				
50	Trial design	<a href="#">#8</a>	Description of trial design including type	7
51			of trial (eg, parallel group, crossover,	
52			factorial, single group), allocation ratio,	
53			and framework (eg, superiority,	
54			equivalence, non-inferiority, exploratory)	
55				
56				
57				
58	<b>Methods:</b>			
59				
60				

1 **Participants,**  
2 **interventions, and**  
3 **outcomes**  
4

5 Study setting	<a href="#">#9</a>	6 Description of study settings (eg, 7 community clinic, academic hospital) and 8 list of countries where data will be 9 collected. Reference to where list of 10 study sites can be obtained	8
13 Eligibility criteria	<a href="#">#10</a>	14 Inclusion and exclusion criteria for 15 participants. If applicable, eligibility 16 criteria for study centres and individuals 17 who will perform the interventions (eg, 18 surgeons, psychotherapists)	8
22 Interventions: 23 description	<a href="#">#11a</a>	24 Interventions for each group with 25 sufficient detail to allow replication, 26 including how and when they will be 27 administered	14
29 Interventions: 30 modifications	<a href="#">#11b</a>	31 Criteria for discontinuing or modifying 32 allocated interventions for a given trial 33 participant (eg, drug dose change in 34 response to harms, participant request, 35 or improving / worsening disease)	14
37 Interventions: 38 adherence	<a href="#">#11c</a>	39 Strategies to improve adherence to 40 intervention protocols, and any 41 procedures for monitoring adherence (eg, 42 drug tablet return; laboratory tests)	15
44 Interventions: 45 concomitant care	<a href="#">#11d</a>	46 Relevant concomitant care and 47 interventions that are permitted or 48 prohibited during the trial	n/a; No restrictions or specific allowances made on any health-related care or interventions during study participation.
52 Outcomes	<a href="#">#12</a>	53 Primary, secondary, and other outcomes, 54 including the specific measurement 55 variable (eg, systolic blood pressure), 56 analysis metric (eg, change from 57 baseline, final value, time to event),	9

method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended

1			
2			
3			
4			
5			
6			
7			
8	Participant timeline	<a href="#">#13</a>	Time schedule of enrolment, 14
9			
10			
11			
12			
13			
14			
15			
16	Sample size	<a href="#">#14</a>	Estimated number of participants needed 7
17			
18			
19			
20			
21			
22			
23			
24			
25	Recruitment	<a href="#">#15</a>	Strategies for achieving adequate 13
26			
27			
28			
29			

## Methods:

### Assignment of interventions (for controlled trials)

30			
31			
32			
33			
34			
35			
36			
37	Allocation:	<a href="#">#16a</a>	Method of generating the allocation n/a; This study uses a single
38	sequence		sequence (eg, computer-generated group assignment with no
39	generation		random numbers), and list of any factors randomization or masking.
40			
41			
42			
43			
44			
45			
46			
47			
48			
49			
50			
51	Allocation	<a href="#">#16b</a>	Mechanism of implementing the n/a; This study uses a single
52	concealment		allocation sequence (eg, central group assignment with no
53	mechanism		telephone; sequentially numbered, randomization or masking.
54			
55			
56			
57			
58			
59			
60			

interventions are assigned

1  
2  
3 Allocation: [#16c](#) Who will generate the allocation n/a; This study uses a single  
4 implementation sequence, who will enrol participants, group assignment with no  
5 and who will assign participants to randomization or masking.  
6 interventions  
7

8  
9 Blinding (masking) [#17a](#) Who will be blinded after assignment to n/a; This study uses a single  
10 interventions (eg, trial participants, care group assignment with no  
11 providers, outcome assessors, data randomization or masking.  
12 analysts), and how  
13  
14

15  
16 Blinding (masking): [#17b](#) If blinded, circumstances under which n/a; This study uses a single  
17 emergency unblinding is permissible, and procedure group assignment with no  
18 unblinding for revealing a participant's allocated randomization or masking.  
19 intervention during the trial  
20  
21

22  
23 **Methods: Data**  
24 **collection,**  
25 **management, and**  
26 **analysis**  
27  
28

29  
30 Data collection plan [#18a](#) Plans for assessment and collection of 10  
31 outcome, baseline, and other trial data,  
32 including any related processes to  
33 promote data quality (eg, duplicate  
34 measurements, training of assessors)  
35 and a description of study instruments  
36 (eg, questionnaires, laboratory tests)  
37 along with their reliability and validity, if  
38 known. Reference to where data  
39 collection forms can be found, if not in  
40 the protocol  
41  
42  
43  
44  
45  
46

47 Data collection [#18b](#) Plans to promote participant retention 15  
48 plan: retention and complete follow-up, including list of  
49 any outcome data to be collected for  
50 participants who discontinue or deviate  
51 from intervention protocols  
52  
53  
54

55 Data management [#19](#) Plans for data entry, coding, security, and 14  
56 storage, including any related processes  
57 to promote data quality (eg, double data  
58  
59



entry; range checks for data values).

Reference to where details of data management procedures can be found, if not in the protocol

1			
2			
3			
4			
5			
6			
7	Statistics:	<a href="#">#20a</a>	15
8	outcomes	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	
9			
10			
11			
12			
13			
14			
15	Statistics:	<a href="#">#20b</a>	16
16	additional analyses	Methods for any additional analyses (eg, subgroup and adjusted analyses)	
17			
18			
19	Statistics: analysis	<a href="#">#20c</a>	16
20	population and	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	
21	missing data		
22			
23			
24			
25			
26			
27	<b>Methods:</b>		
28	<b>Monitoring</b>		
29			
30			
31	Data monitoring:	<a href="#">#21a</a>	n/a; IRB designated study
32	formal committee	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	minimal risk; all data monitoring occurs internally by the co-principle investigators.
33			
34			
35			
36			
37			
38			
39			
40			
41			
42			
43			
44			
45	Data monitoring:	<a href="#">#21b</a>	n/a; Plans for interim
46	interim analysis	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	analyses are detailed in the IRB-approved data safety monitoring plan and are not described fully in the protocol manuscript.
47			
48			
49			
50			
51			
52			
53			
54			
55	Harms	<a href="#">#22</a>	n/a; Plans for adverse
56		Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events	events are detailed in the IRB-approved data safety
57			
58			
59			
60			

1		and other unintended effects of trial	monitoring plan and are not
2		interventions or trial conduct	described fully in the
3			protocol manuscript.
4			
5	Auditing	<a href="#">#23</a> Frequency and procedures for auditing	n/a; Plans for trial conduct
6		trial conduct, if any, and whether the	audits are detailed in the
7		process will be independent from	IRB-approved data safety
8		investigators and the sponsor	monitoring plan and are not
9			described fully in the
10			protocol manuscript.
11			
12			
13			
14			
15	<b>Ethics and</b>		
16	<b>dissemination</b>		
17			
18			
19	Research ethics	<a href="#">#24</a> Plans for seeking research ethics	17
20	approval	committee / institutional review board	
21		(REC / IRB) approval	
22			
23			
24	Protocol	<a href="#">#25</a> Plans for communicating important	15
25	amendments	protocol modifications (eg, changes to	
26		eligibility criteria, outcomes, analyses) to	
27		relevant parties (eg, investigators, REC /	
28		IRBs, trial participants, trial registries,	
29		journals, regulators)	
30			
31			
32			
33			
34	Consent or assent	<a href="#">#26a</a> Who will obtain informed consent or	14
35		assent from potential trial participants or	
36		authorised surrogates, and how (see	
37		Item 32)	
38			
39			
40			
41	Consent or assent:	<a href="#">#26b</a> Additional consent provisions for	29
42	ancillary studies	collection and use of participant data and	
43		biological specimens in ancillary studies,	
44		if applicable	
45			
46			
47			
48	Confidentiality	<a href="#">#27</a> How personal information about potential	17; IRB approval has been
49		and enrolled participants will be	obtained for all aspects of
50		collected, shared, and maintained in	the study, including the
51		order to protect confidentiality before,	collection and protection of
52		during, and after the trial	participant confidentiality
53			and personal information
54			
55			
56			
57			
58	Declaration of	<a href="#">#28</a> Financial and other competing interests	27
59			
60			

1	interests		for principal investigators for the overall trial and each study site	
2				
3				
4	Data access	<a href="#">#29</a>	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	n/a; Data access enumerated in the IRB-approved Data Safety Monitoring Plan and protocol
5				
6				
7				
8				
9				
10				
11	Ancillary and post trial care	<a href="#">#30</a>	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	n/a; This trial has been designated as minimal risk by the UAB IRB.
12				
13				
14				
15				
16	Dissemination	<a href="#">#31a</a>	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	17
17	policy: trial results			
18				
19				
20				
21				
22				
23				
24				
25				
26				
27	Dissemination	<a href="#">#31b</a>	Authorship eligibility guidelines and any intended use of professional writers	n/a; Author contributions detailed on page 27 and no professional writers were used
28	policy: authorship			
29				
30				
31				
32				
33				
34	Dissemination	<a href="#">#31c</a>	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	n/a; No current plans exist for granting public access to full protocol, participant dataset, or statistical code.
35	policy: reproducible			
36	research			
37				
38				
39				
40				
41	<b>Appendices</b>			
42				
43	Informed consent	<a href="#">#32</a>	Model consent form and other related documentation given to participants and authorised surrogates	29
44	materials			
45				
46				
47				
48				
49	Biological	<a href="#">#33</a>	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	n/a; This study collects no biological specimen.
50	specimens			
51				
52				
53				
54				
55				
56				
57	Notes:			
58				
59				
60				

- 1 • 5c: n/a; This funding source and sponsor had no role in the design of this study and will not have  
2 any role during its execution, analyses, interpretation of the data, or decision to submit results.  
3
- 4 • 5d: n/a; IRB has designated the study minimal risk; all aspects of the trial are overseen by the co-  
5 PIs and research team  
6
- 7 • 6b: n/a; Single Group Assignment  
8
- 9 • 11d: n/a; no restrictions or specific allowances made on any health-related care or interventions  
10 during study participation.  
11
- 12 • 16a: n/a; This study uses a single group assignment with no randomization or masking.  
13
- 14 • 16b: n/a; This study uses a single group assignment with no randomization or masking.  
15
- 16 • 16c: n/a; This study uses a single group assignment with no randomization or masking.  
17
- 18 • 17a: n/a; This study uses a single group assignment with no randomization or masking.  
19
- 20 • 17b: n/a; This study uses a single group assignment with no randomization or masking.  
21
- 22 • 21a: n/a; IRB designated study minimal risk; all data monitoring occurs internally by the co-  
23 principle investigators.  
24
- 25 • 21b: n/a; Plans for interim analyses are detailed in the IRB-approved data safety monitoring plan  
26 and are not described fully in the protocol manuscript.  
27
- 28 • 22: n/a; Plans for adverse events are detailed in the IRB-approved data safety monitoring plan  
29 and are not described fully in the protocol manuscript.  
30
- 31 • 23: n/a; Plans for trial conduct audits are detailed in the IRB-approved data safety monitoring  
32 plan and are not described fully in the protocol manuscript.  
33
- 34 • 26b: n/a; ancillary study consent not included in protocol manuscript  
35
- 36 • 27: 17; IRB approval has been obtained for all aspects of the study, including the collection and  
37 protection of participant confidentiality and personal information  
38
- 39 • 29: n/a; Data access enumerated in the IRB-approved Data Safety Monitoring Plan and protocol  
40
- 41 • 30: n/a; This trial has been designated as minimal risk by the UAB IRB.  
42
- 43 • 31b: n/a; author contributions detailed on page 27 and no professional writers used  
44
- 45 • 31c: n/a; no current plans exist for granting public access to full protocol, participant dataset, or  
46 statistical code.  
47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 33: n/a; This study collects no biological specimen. The SPIRIT Explanation and Elaboration paper is distributed under the terms of the Creative Commons Attribution License CC-BY-NC. This checklist was completed on 19. April 2023 using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

For peer review only